 
Study Title  A Prospective, Randomized, Double -Blind, Dose -Comparison 
Concurrent Control Study to Assess the Safety and Tolerability of 
GRF6019 Infusions in Subjects with Mild to Moderate Alzheimer’s 
Disease  
NCT Number  [STUDY_ID_REMOVED]  
Document Description  Protocol  (Version 7.0) 
Document Date  02 November  2018  
 

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
__________________________________________________________________________________________  
CONFIDENTIAL/PROPRIETARY   Page 1 of 100  
 
A Prospective, Randomized, Double -Blind, Dose -Comparison Concurrent Control Study to 
Assess the Safety and Tolerability of GRF6019 Infusions in Subjects with Mild to Moderate 
Alzheimer’s Disease  
 
Protocol  Number : ALK6019 -201 
Clinical Phase : 2 
Sponsor : Alkahest, Inc.  
[ADDRESS_1020705], Suite D 
San Carlos, CA [ZIP_CODE]  
Investigational Drug : GRF6019  
Indication : Alzheimer’s Disease   
Authorized Representative :  
 
[ADDRESS_1020706], Suite D 
San Carlos, CA [ZIP_CODE] 
Telephone: [PHONE_15571] 
Fax: 650 -801-0480  
Principal Investigator :  
[CONTACT_378829] : V7.0 
Version Date : 02NOV 2018  
Replaces Version (s): V6.0, 12OCT 2018  
 
CONFIDENTIAL STATEMENT  
The information contained in this document and all information provided as related to this clinical study are the confidential and proprietary information of the Sponsor and except as may be required by [CONTACT_1032], state or 
local laws or regulations may not be disclosed to others without prior written permission of the Sponsor.  The Principal Investigator [INVESTIGATOR_113961], however, disclose such information to supervised individuals working on the clinical study, provided such individuals agree to maintain the confidentiality of such information.
 
 
 

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
__________________________________________________________________________________________  
CONFIDENTIAL/PROPRIETARY   Page [ADDRESS_1020707] OF DEFINITIONS  ........................................................................................................................................................ 8  
PROTOCOL APPROVAL PAGE  .......................................................................................................................................... 9  
STATEMENT OF COMPLIANCE  ...................................................................................................................................... 10 
PROTOCOL SUMMARY  .................................................................................................................................................... 11 
SCHEMATIC OF STUDY DESIGN  ................................................................................................................................... 13 
1 KEY ROLES  ................................................................................................................................................................. 13 
1.1 AUTHORIZED REPRESENTATIVE (SIGNATORY) / RESPONSIBLE PARTY  ........................................... 13 
1.2 STUDY ORGANIZATION .................................................................................................................................. 13 
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ..................................... [ADDRESS_1020708] WITHDRAWAL OR TERMINATION  .............................................................................................. 22 
5.4.1  REASONS FOR WITHDRAWAL OR TERMINATION  ............................................................................ 22 
5.4.2 HAN
DLING OF PARTICIPANT WITHDRAWALS OR TERMINATION  .............................................. 22 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
__________________________________________________________________________________________  
CONFIDENTIAL/PROPRIETARY   Page 3 of 100  
5.5 PREMATURE TERMINATION OR SUSPENSIO N OF STUDY  ...................................................................... 23 
6 STUDY AGENT  ........................................................................................................................................................... 23 
6.1 STUDY AGENT(S) AND CONTROL DESCRIPTION  ...................................................................................... [ADDRESS_1020709] STORAGE AND STABILITY ................................................................................................. 24 
6.1.4  PREPARATION  ........................................................................................................................................... 24 
6.1.5  DOSING AND ADMINISTRATION  .......................................................................................................... 24 
6.1.6  ROUTE OF ADMINISTRATION  ................................................................................................................ 24 
6.1.7  DOSING SCHEDULE  .................................................................................................................................. 25 
6.1.8  DURATION OF THERAPY ........................................................................................................................ 25 
6.2 STUDY AGENT ACCOUNTABILITY ............................................................................................................... 25 
7 STUDY PROCEDURES AND SCHEDULE  ............................................................................................................... 26 
7.1 STUDY PROCEDURES/EVALUATIONS  ......................................................................................................... 26 
7.1.1  STUDY SPECIFIC PROCEDURES  ............................................................................................................ 26 
7.2 LABORATORY PROCEDURES/EVALUATIONS  ........................................................................................... 33 
7.2.1  CLINICAL LABORATORY EVALUATIONS  ........................................................................................... 33 
7.2.2  OTHER ASSAYS OR PROCEDURES  ........................................................................................................ 33 
7.2.3  SPECIMEN PREPARATION, HANDLING, STORAGE, AND SHIPPI[INVESTIGATOR_1645]  ............................................. 35 
7.3 STUDY SCHEDULE  ........................................................................................................................................... 35 
7.3.1  SCREENING ................................................................................................................................................ 35 
7.3.2  BASELINE  ................................................................................................................................................... 36 
7.3.3  RANDOMIZATION  ..................................................................................................................................... 36 
7.3.4  TREATMENT .............................................................................................................................................. 37 
7.3.5  FOLLOW-UP  ................................................................................................................................................ 37 
7.3.6  FINAL STUDY VISIT  ................................................................................................................................. 39 
7.3.7  EARLY TERMINATION  ............................................................................................................................. 39 
7.3.8 SC
HEDULE OF EVENTS TABLE .............................................................................................................. 39 
7.4 CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES  ................................................... 39 
7.5 PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDURES  ......................................................... 40 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
__________________________________________________________________________________________  
CONFIDENTIAL/PROPRIETARY   Page 4 of 100  
8 ASSESSMENT OF SAFETY  ....................................................................................................................................... 40 
8.1 SPECIFICATION OF SAFETY PARAMETERS ................................................................................................ 40 
8.1.1  DEFINITION OF ADVERSE EVENTS (AE)  ............................................................................................. 40 
8.1.2  DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  ......................................................................... [ADDRESS_1020710] ......................................................................................... 46 
8.4.4  REPORTING OF PREGNANCY  ................................................................................................................. 46 
8.5 STUDY HALTING RULES  ................................................................................................................................. 46 
8.6 SAFETY OVERSIGHT  ........................................................................................................................................ 47 
9 CLINICAL MONITORING  ......................................................................................................................................... 47 
10 STATISTICAL CONSIDERATIONS  ...................................................................................................................... 48 
10.1 STATISTICAL AND ANALYTICAL PLANS  ................................................................................................... 48 
10.2 STATISTICAL HYPOTHESES ........................................................................................................................... 48 
10.3 ANALYSIS DATASETS  ..................................................................................................................................... 48 
10.4 DESCRIPTION OF STATISTICAL METHODS  ................................................................................................ 48 
10.4.1  GENERAL APPROACH  .............................................................................................................................. 48 
10.4.2  ANALYSIS OF THE PRIMARY ENDPOINT(S)  ....................................................................................... 49 
10.4.3  ANALYSIS OF THE SECONDARY ENPOINT(S)  .................................................................................... 49 
10.4.4  SAFETY ANALYSES  .................................................................................................................................. 49 
10.4.5  ADHER E NCE AND RETENTION ANALYSES  ........................................................................................ 50 
10.4.6  BASELINE DESCRIPTIVE STATISTICS .................................................................................................. 50 
10.4.7  PLANNED INTERIM ANALYSES  ............................................................................................................. 50 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
__________________________________________________________________________________________  
CONFIDENTIAL/PROPRIETARY   Page 5 of 100  
10.4.8  ADDITIONAL SUB -GROUP ANALYSES  ................................................................................................ 50 
10.4.9  MULTIPLE COMPARISON/MULTIPLICITY  ........................................................................................... 50 
10.4.10  TABULATION OF INDIVIDUAL RESPONSE DATA  ......................................................................... 50 
10.4.11  EXPLORATORY ANALYSES  ................................................................................................................ 50 
10.5 SAMPLE SIZE ..................................................................................................................................................... 51 
10.6 MEASURE TO MINIMIZE BIAS ....................................................................................................................... 51 
10.6.1  ENROLLMENT/RANDOMIZATION/MASKING PROCEDURES  .......................................................... 51 
10.6.2  EVALUATION OF SUCCESS OF BLINDING  .......................................................................................... 52 
10.6.3  BREAKING THE STUDY BLIND/PARTICIPANT CODE  ....................................................................... 52 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  .................................................. 52 
12 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................................................................................ [ADDRESS_1020711]  ................................................................................................................. 53 
12.3 INFORMED CONSENT PROCESS  .................................................................................................................... 53 
12.3.1  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS .......................................................................................................................................................... [ADDRESS_1020712] POLICY  ............................................................ 57 
15 LITERATURE REFERENCES ................................................................................................................................ 58 
16 APPENDICES  .......................................................................................................................................................... 61 
17 SCH ED
ULE OF EVENTS  ....................................................................................................................................... 83 
18 REVISION HISTORY  .............................................................................................................................................. 85 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
__________________________________________________________________________________________  
CONFIDENTIAL/PROPRIETARY   Page [ADDRESS_1020713] OF ABBREVIATIONS  
AD Alzheimer’s Disease  
ADAS -Cog/11  Alzheimer’s Disease Assessment Scale -Cognitive Subscale  
ADCS -ADL 23 Alzheimer’s Disease Cooperative Study – Activities of Daily Living 23 
ADCS -CGIC  Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change rating  
AE Adverse Event  
ApoE  Apolipoprotein E  
ARIA  Amyloid Related Imaging Abnormalities  
ASL  Arterial Spin Labeling  
BLA  Biologics License Application  
CDR -SOB  Clinical Dementia Rating Scale – Sum of Boxes  
CFR  Code of Federal Regulations  
CFT Category Fluency Test  
CLIA  Clinical Laboratory Improvement Amendments  
CMP  Clinical Monitoring Plan  
CRF  Case Report Form  
CSF Cerebrospi[INVESTIGATOR_746230]  
C-SSRS  Columbia -Suicide Severity Rating Scale  
ECG  Electrocardiogram  
eGFR  Estimated Glomerular Filtration Rate  
FDA  Food and Drug Administration  
fMRI  Functional  Magnetic Resonance Imaging  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICH International Conference on Harmonization  
ICH E6 R2  International Conference on Harmonization Guidance for Industry, Good Clinical Practice: 
Cons olidated Guidance, Revision [ADDRESS_1020714]  
ITT Intent -To-Treat  
IV Intravenous  
MedDRA  Medical Dictionary for Regulatory Activities  
MHIS  Modified Hachinski Ischemia Scale  
MMSE  Mini -Mental State Examination  
MRI  Magnetic Resonance Imaging  
NIA-AA National Institute on Aging -Alzheimer’s Association  
NODscid  Non-obese diabetic severe combined immunodeficiency  
NPI-Q Neuropsychiatric Inventory Questionnaire  
NSG  NODscid Gamma  
PET Positron -Emission Tomograph y 
PT Preferred Term  
SAE  Serious Adverse Event  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
__________________________________________________________________________________________  
CONFIDENTIAL/PROPRIETARY   Page 7 of 100  
SOC  System Organ Class  
S[LOCATION_003]RS  Suspected Unexpected Serious Adverse Reactions  
UPCR  Urine Protein -to-Creatinine Ratio  
vMRI  Volumetric Magnetic Resonance Imaging  
WHO  World Health Organization  
 
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
__________________________________________________________________________________________  
CONFIDENTIAL/PROPRIETARY   Page [ADDRESS_1020715] and 
collecting and/or managing adverse events (AEs) that occur before, during, and 
after the Infusion Period.  
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 9 of 100  
PROTOCOL APPROVAL PAGE 
 
  
Study Title:  A Prospective,  Randomized, Double -Blind , Dose -Comparison 
Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subject s with Mild to Moderate Alzheimer’s 
Disease  
Protocol Number:  ALK6019 -201 
Version/Date:  V7.0_02NOV2 018 
Sponsor Name [CONTACT_13311]:  
 Alkahest, Inc.  
[ADDRESS_1020716] relevant version, and app licable legal and regulatory 
requirements.  
     
Approved by:      
   
     
[INVESTIGATOR_12174] (print)   Signature   [CONTACT_746304]# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 10 of 100  
STATEMENT OF COMPLIANCE  
Protocol Title:  A Prospective,  Randomized, Double -Blind , Dose -Comparison Concurrent Control  
Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subject s with Mild 
to Moderate Alzheimer’s Disease  
Protocol Number:  ALK6019 -201 Protocol Version 7.0_02NOV 2018  
 
By [CONTACT_27616], I: 
• Confirm that my staff and I have carefully read and understand this protocol or protocol amendment 
and are thoroughly familiar with the appropriate use of the investigational drug described herein. 
• Agree to comply with the conduct and terms of the study specified herein and with any other study 
conduct procedures provided by [CONTACT_1034], Alkahest, Inc., or their designee 
• Agree to assume responsibility for the proper conduct of the study at this site, including complying with current relevant versions of the US Food and Drug Administration (FDA) regulations, the International Conference on Harmonization (ICH) GCP guidelines, the Declaration of Helsinki, and all applicable 
rules, regulations, and federal, state, and local laws relating to the conduct of clinical studies and the 
protection of human subjects.  
• Agree not to implement deviations from or changes to the protocol or protocol amendments without 
agreement from the Sponsor and prior submission to and written approval (where required) from the 
Institutional Review Board (IRB) or Independent Ethics Committee (IEC), except when necessary to 
eliminate an immediate hazard to the subjects, or for administrative aspects of the study (where 
permitted by [CONTACT_72016]).  
• Agree to onsite monitoring of all source documents by [CONTACT_124546], Inc. or designee and to on- site 
inspection of source documents by [CONTACT_4708], including but not limited to the FDA, local governing regulatory bodies, and IRB/IEC inspectors. 
   
Investigator's Signature   [CONTACT_746305]# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 11 of 100  
PROTOCOL SUMMARY  
  
Title:  A Prospective, Randomized, Double -Blind, Dose -Comparison Concurrent Control  Study to 
Assess the Safety and Tolerability of GRF6019 Infusions in Subjects with Mild to Moderate 
Alzheimer’s Disease (AD)  
 
Précis:  This is a  prospective, randomized, double -blind, dose -comparison concurrent control study 
to assess the safety, tolerability, and feasibility of GRF6019, a human plasma protein 
fraction , administered by [CONTACT_33980] ( IV) infusion to subjects with mild to moderate AD.  
 
Subjects will be  randomized to one of two doses of active treatment in a double-blind 
manner: [ADDRESS_1020717] a total study duration of  
approximately 7 months.  
 The infusion duration for a ll subjects will be between  2 hours  to a maximum of 3 hours  to 
maintain blinding.  Flow rates will be titrated  according to dose -specific guidelines  to ensure 
that the entire assigned dose is administered  during this interval .  The following measures 
will be taken to ensure adequate allocation concealment during infusions: blinding of subjects, trial partners, study coordinators, physicians, and cognitive test administrators to treatment dose; use of blinded Outcomes Assessors and unblinded Infusion Nurses; standard 
time for attachment to the IV infusion setup (up to 180 minutes); and measures to block 
view of vial(s)  and infusion pump throughout the infusion.  
 All subjects will undergo a screening visit, baseline visit, treatment visits, follow -up visits 
and an end of study/early termination visit .  During each 5-day dosing period, subjects will 
reside in inpatient units to facilitate safety evaluation.  Subjects will be discharged from the 
inpatient facility the day afte r the 5 th day of dosing.  Safety and tolerability assessments will 
occur at every visit .  Neurocognitive and motor assessments will be performed at baseline 
and at periodic interim visits following dosing.  Subjects who are eligible and consent to 
participate in the optional cerebrospi[INVESTIGATOR_872] (CSF) biomarker research  will undergo two 
lumbar punctures for CSF collection, the first occurring prior to initial dosing, and the 
second occurring following final dosing.   
 
Objectives:  The primary objective of the study is to assess the safety, tolerability , and feasibility of 2 
dose levels of GRF6019 in subjects with mild  to moderate AD.  As a secondary objective, 
the study will assess the potential effects on cognition of the 2 dose levels using various 
cognitive measures.  The exploratory objective s include  changes on MRI and analysis of 
blood  and CSF  for specific biomarkers associated with AD.  
 
Endpoints:  Primary endpoints will be assessed as follows:  
• Incidence of treatment-emergent adverse events (AEs) identified by [CONTACT_84220] (PT) and grouped by [CONTACT_7204]. 
• Feasibility and tolerability of each dose level. 
 
Secondary efficacy endpoints w ill be assesse d as follows:  

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 12 of 100  
• Changes in scores on the Mini -Mental State Examination (MMSE) . 
• Changes in scores on the 11-item Alzheimer’s Disease Assessment Scale-Cognitive 
Subscale (ADAS -Cog/11) . 
• Changes in scores on the Grooved Pegboard Test . 
• Changes in scores on the Category Fluency Test (CFT) . 
• Changes in the Clinical Dementia Rating Scale – Sum of Boxes ( CDR -SOB). 
• Changes in the Alzheimer’s Disease Cooperative Study – Activities of Daily Living 23 
(ADCS -ADL 23). 
• Changes on the Alzheimer’s Disease Cooperative Study – Clinical Global Impression of 
Change rating (ADCS -CGIC). 
• Changes on the Neuropsychiatric Inventory Questionnaire (NPI -Q). 
• Changes in the Savonix Neurocognitive Assessments and Digit Span . 
 
Secondary safety endpoints will be assessed as follows:  
• Changes from baseline in clinical laboratory parameters.  
• Changes from baseline in vital sign measurements. 
• Changes from baseline in the Columbia -Suicide Severity Rating Scale (C-SSRS). 
• Changes on MRI scans designed to assess for Amyloid Related Imaging Abnormalities 
(ARIA). 
 Secondary feasibility end point will be assessed by : 
• Subject compliance with the study visit schedule  and study visit procedures  
• Subject retention  
• Success of blinding  
 Explorator y endpoints will be assessed as follows:  
• Changes in imaging endpoints such as volumetric MRI (vMRI), functional  
MRI (fMRI), and Arter ial Spin Labeling (ASL)   
• Changes in blood-based biomarkers  
• Changes in CSF biomarkers (in participating subjects) 
 
Population:  Approximately 40 subjects  between 60 and 90 years of age with a diagnosis of probable 
mild to moderate AD.  Assuming a drop -out rate of 25%, enrollment at this level will yield 
approximately 30 evaluable subjects.   
 
Phase:  2 
Number of Sites:  Up to 10 sites in the [LOCATION_002]  
Description  of 
Study Agent:  GRF6019: A human p lasma protein fraction for IV infusion  
 
Study Duration:  Approximately 15 months  
Participant 
Duration:  Approximately 7 months   
  

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 13 of 100  
SCHEMATIC OF STUDY DESIGN  
  
 
 
 
1 KEY ROLES   
1.1 AUTHORIZED REPRESENTATIVE (SIGNATORY) / RESPONSIBLE PARTY  
 
 
Alkahest
, Inc.  
[ADDRESS_1020718], Suite D  
San Carlos, CA [ZIP_CODE]  
Telephone: 650-[ADDRESS_1020719] information of the responsible party and individuals involved with the study (e.g., investigator(s), 
Sponsor’s medical expert [INVESTIGATOR_289174], Sponsor’s representative(s), laboratories, steering committees, and oversight committees [ including independent ethics committees (I ECs)  and Institutional Review Boards (IRBs)], as 
applicable) will be maintained by [CONTACT_322568].  
 
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
2.1 BACKGROUND INFORMATION  
Alzheimer’s Disease (AD) is a progressive pathophysiological disorder  associated with cognitive decline.  The initial 
symptoms typi[INVESTIGATOR_746231], whereas memory for remote events may be spared until late stage disease.  As of [ADDRESS_1020720] AD.  This number includes an 
estimated 5. 5 million people age 65 and older .  By [CONTACT_20169] -century, that number is expected to grow to 14 million.  By 2050  
nearly 1 million new  cases will be diagnosed per year ( Alzheimer’s Association 2018
).  
During the course of the disease, synapses and ultimately neurons are lost within the cerebral cortex, hippocampus, and 
subcortical structures (including selective cell loss in the nucleus basalis of Meynert), locus coeruleus, and nucleus raphe 
dorsalis.  Cerebral glucose use and perfusion is reduced in some areas of the brain (e.g., the parietal lobe and temporal 
cortices in early -stage disease, prefrontal cortex in late -stage disease) .  Neuritic or senile plaques (composed of neurites, 

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 14 of 100  
astrocytes, and glial cells around an amyloid core) and neurofibrillary tangles (composed of paired helical filaments) are 
likely to play a role in the pathogenesis of AD .  The pathologic changes often precede symptoms of impaired cognition 
and memory ( Mayeux 2010 ). 
Effectiveness of existing approved therapi[INVESTIGATOR_014], including acetyl cholinesterase inhibitors (e.g., donepezil ) and N-Methyl -D-
aspartic acid (NMDA) receptor agonists  (e.g., memantine) varies across the population .  These drugs neither  provide 
relief from all symptoms of AD nor do they prevent the long-term progression  of the di sease .  There are currently no 
disease modifying agents for use in AD ( Alzheimer’s Association 2018 ) and  given the increasing prevalence and 
socioeconomic impact of the disease, identifying treatments for maintaining or improving cognitive function is an area of 
substantial unmet medical need .   
In [ADDRESS_1020721] the aging brain, and that rejuvenating factors from young animals may ameliorate the 
effects of aging ( Villeda 201 1).  Following their initial findings, the same team of investigators performed a study to 
explore the therapeutic effects of systemic exposure of aged mice to young plasma by [CONTACT_411214] ( Villeda 2014 ).  At 
the cognitive level, systemic administration of young plasma into aged mice improved age -related impairments.  In 
addition, the data demonstrated that exposure of old mice to young plasma counteracts age-related impairment at the 
molecular and structural levels in the hippocampus ( Villeda 2014 ).  These studies lay t he foundation for the hypothesis 
that soluble circulating factors from young plasma may have beneficial effects on human cognition .   
Results from nonclinical studies conducted at Alkahest (see Section 2.2, “Rationale”  below) suggest there is a beneficial 
effect of young human plasma and plasma protein fraction in age -related cognitive decline and histopathological 
endpoints in mouse models .  These studies have rai sed the intriguing possibility that there are factors present in human 
plasma that may prove beneficial against brain aging and ameliorate some of the age-associated memory impairments in 
people, especially in those experiencing rapid cognitive decline fro m ag e-associated neurodegenerative diseases.   
2.[ADDRESS_1020722] ’s study ALK6019 -201 will evaluate 2 dos e levels of GRF6019  administered via intravenous  (IV) infusion.  
GRF6019 has been  manufactured  specifically for investigational purposes .  It is a purified  plasma protein fraction  
made from pooled human plasma  
.   
 
The rationale for using a plasma protein fraction was based on several factors.  Although plasma is widely used and 
considered safe, there are inherent risks such as the potential transfer of unknown pathogens to recipi[INVESTIGATOR_840], 
histoincompatibility , and allergic reactions to proteins such as clotting factors and immunoglobulins .  Therefor e, the 
Blood Products Industry has developed safer products based on pooling plasma of highly selected donations, 
fractionating them into more defined products , and adding additional processing steps to reduce the potential for 
pathogen transmission .  Leveraging this fractionation technology,  GRF6019 is a 
 
 Nonclinical  studies conducted at Alkahest have demonstrated that both young whole plasma and  
 plasma protein fraction  confer beneficial outcomes in age -related cognitive decline and histopathological 
endpoints in mouse models (  

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 15 of 100  
).  M ild to 
moderate AD patients will be selected for inclusion  in th is clinical study as they have identifiable deficits in cognitive 
function and suffer from a  disease with limited treatment options , making them  a population for whom the balance of 
risk to potential ben efit of treatment with GRF6019 is reasonable.     
 
Noncli
nical studies were initiated at Alkahest to test whether the positive effects observed with young mouse plasma 
could be replicated using  human plasma .  Treatment of aged NODscid (non-obese diabetic severe combined 
immunodeficiency) mice with  human plasma (100-150  µl per injection, two injections per week for 3 -5 
weeks) resulted in improved cognitive and motor performance in standard behavioral tests .  These cognitive changes 
were further supported by [CONTACT_746267] .  Together, these results 
provide d support for the hypothesis that  plasma infusions may have functional benefits to man, potentially 
ameliorating or halting the progression of cognitive decline associated with AD    
 
Noncl i
nical studies conducted at Alkahest evaluated the effects of both young plasma and plasma protein fraction using 
various dosing paradigms in NODscid, NSG (NODscid Gamma) and C57BL/6J mice.  Initially, mice were dosed with 
150 µL of  plasma,  plasma protein fraction or saline (control) via IV infusions 2 times per week for 5 weeks 
( ).  A subsequent study examined the same dosing regimen for a period of 23 weeks, to assess the effects 
of treatment on ag e-depe n dent changes in behavioral and cognitive function over a period of  approximately 6 months 
( ).  Following these early studies, a novel dosing regimen of 150 µL for 7 consecutive days (referred to 
as “pu l
sed dosing”) was evaluat ed both alone and compared to other intermittent weekly dosing regimens (
).  A fi
nal study examined pulsed dosing of 150 µL for 5 
consecu
tive days ( ), which is the pulsed dosing reg imen chosen for ALK6019 -201.  
 Based o
n these nonclinical  studies, significant improvements in cognitive performance and histological correlates  were 
observed  with a  plasma protein fraction .  In addition, studies with  plasma demonstrated that the beneficial 
effect was observed long after initial dosing, indicating there is not a requirement for continuous repeat dosing.  The effects were long-lived but  did diminish over time such that [ADDRESS_1020723] reached significance .   
 Together, these studies indicate that 5 consecutive days of dosing (“pulsed dosing”) of GRF6019, a batch o  
 
  If safety and efficacy are 
demonstrated  with GRF6019, pulsed dosing may be more convenient than weekly or monthly dosing for patients.   
 A prospective, randomized, double -blind , dose-comparison concurrent control study design  has been selected  to reduce 
or eliminate bias while facilitating the identification of  a safe and feasible dosing paradigm, trends in changes of 
neurocognitive endpoints , and potential plasma derived factors that may affect these parameters.  Within -patient and 
between -group cognitive changes associated with the [ADDRESS_1020724] specific hypotheses regarding changes in cognitive function, the results are nevertheless expected to lay the 
foundation for larger trials designed and powered to characterize the potential benefit s of GRF6019 in AD and other 
neurodegenerative disorders typi[INVESTIGATOR_746232].  
 Human dos e levels were selected based on known safety through clinical experience in man and scaling from efficacy in 
nonclinical  studies.  No safety concerns were observed in nonclinical studies using repeated doses of 150 µL in mice.  In 
determining potent ially ef ficacious human dos es, different methods can be used.  Allometric scaling is primarily 
performed based on body surface area conversion in mg/m
2.  Using allometric scaling,  a dose of 150 µL yields an 

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 16 of 100  
equivalent human dose  using body surface area scaling  of 28.4 mL.  Allometric scaling is used for small molecules 
whose elimination is dependent on hepatic metabolism. Alternative scaling methods include mg/kg (recommended for 
macromolecules >100 kDa) and volumetric scaling based on relative blood vol umes. Because GRF60 19 contains a 
complex mixture of proteins with a molecular weight predominantly <100kDa), and because the beneficial effects of 
these proteins on cognition are believed to occur in the circulation, the concentration of these proteins per  blood volume 
may be the scaling method most likely to accurately estimate the human potential effective dose.   
 
Using isometric scaling based on blood volume, the mouse dose of [ADDRESS_1020725] (known as “plasma” or “fresh frozen plasma”) or as source material for the production of pharmaceutical fractionated products (known as “plasma products” or “plasma derivatives”) (Burnouf 2007
).  GRF6019, a  human plasma protein fraction,  
erves as a viable source of soluble, infusible plasma proteins from  healthy donors .  
 
 
 
 
 
  ABO 
antigen  typi[INVESTIGATOR_746233].  Fina lly, the additional steps taken during production to remove viral pathogens provide an increased 
margin of pathogen safety in comparison to fresh frozen plasma .   
 GRF6019 is not expected to significantly alter the 
urinalyses of recipi[INVESTIGATOR_840], their bleeding times, coagulation times, prothrombin times, prothrombin consumption, plate
let counts or fibrinogen levels when given in quantities of up to 1000 mL.  Hypotension may occur, particularly 
following rapid infusion or intraarterial administration to patients on cardiopulmonary by[CONTACT_6476] .  The blood pressure 
may normalize spontaneously after the slowing or discontinuation of the infusion.   

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 17 of 100  
 
 
 
GRF 6019 
is made from human plasma and may carry a risk of transmitting infectious agents, e .g., viruses, the 
variant Creutzfeldt -Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent .  The 
risk that GRF6019 can transmit an infectious ag ent has been reduced by [CONTACT_339846], 
testing donated plasma, and including manufacturing steps with the capacity to inactivate and/or remove pathogens .   
 
2.3.2  KNOWN POTENTIAL BENEFITS 
 There is no known reported benefit of administering GRF6019 to patient s with mild to moderate AD.  However, if 
the findings in the nonclinical models are replicated in humans, there could be a substantial benefit to individual 
patients, including improvements in cognitive function,  executive cognitive function, daily function, and/or 
neuropsychiatric symptoms .   
 
3 OBJECTIVES AND PURPOSE  
The primary objective of this study is to assess the safety, tolerability , and feasibility of GRF6019, a  human plasma 
protein fraction administered by [CONTACT_746268] .  Secondarily, this study aims to 
assess the effects of the study agent  on subjects’ cognitive function .  As an exploratory objective, blood and plasma  will 
be collected and analyzed to ident ify specific biomarkers associated with cognitive functional changes and/or indicators 
of AD progression .  In addition, subjects who are eligible and consent to participate in the optional CSF biomarker 
research at participating sites will undergo two lumbar punctures for CSF collection.  The CSF will then be utilized to 
assess the potential therapeutic effects of GRF6019 on AD biomarkers of neuronal death, synaptic function, inflammation, and growth factors.  Finally, changes in  imaging results as measured by [CONTACT_746269] (vMRI), functional MRI (fMRI), and Arterial Spin Labeling (ASL) may be evaluated  to identify potential 
indicators of AD progression  and potential therapeutic effect  
 
4 STUDY DESIGN AND ENDPOINTS  
4.1 DESCRIP TION OF THE STUDY DESIGN  
This is a prospective, randomized, double -blind , dose-comparison concurrent control  study conducted at up to 10 sites in 
the [LOCATION_002].   
 Study subjects  will be  dosed for 5 consecutive days (“pulsed dosing”) with GRF6019 during two dosing periods  over the 
approximately 6-month treatment  period.  Subjects will be randomized to one of two dose levels:  [ADDRESS_1020726] the option to stay with the subjects or may seek lodging nearby. 
 Subjects will be invited to participate in optional CSF biomarker research at participating sites.  The CSF collection 
procedure, as well as the potential risks and benefits, will be explained to all study participants.  Participation in the CS F 

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020727] has withdrawn 
consent .  Dosing groups will be stratified by [CONTACT_4321] .  A comprehensive efficacy and safety assessment of all data in toto  will 
be conducted at the end of the study.  
 The overall duration of the study is approximately 15 months from study initiation (i.e., first subject enrolled) to study 
completion (i.e., last subject last visit).  The recruitment period is expected to be approximately [ADDRESS_1020728] 
participation period is approximately 7 months  from screening through end of study, unless prematurely discontinued.  
 
4.2 STUDY ENDPOINTS  
 
4.2.1  PRIMARY ENDPOINT S 
 
The primary endpoints in this study pertain to the safety, tolerability and feasibility of each dos e level. 
 Safety endpoints are as follows:  
• Incidence of treatment-emergent adverse events (AEs) identified by [CONTACT_6213] (PT) and 
grouped by [CONTACT_7204] (SOC) . 
 
Tolerability endpoints are as follows:  
• Number of subjects completing 8 weeks (i.e. through Visit 10)  after receiving at least 5 infusions. 
• Number of subjects completing 24 weeks (i.e. through  End of Study)  after receiving at least 10 infusions . 
 
Feasibility endpoints are as follows:  
• Number of subjects completing [ADDRESS_1020729] statistically significant differences in cognitive or motor 
domains between the Baseline and End of Study values.  However secondary cognitive endpoints will be 
summarized over the study period from Baseline values using descriptive statistics:  
• Changes in scores on the Mini -Mental State Examination (MMSE) ( Folstein 1975 ) (Appendix 1 ). 
• Changes in scores on the 11-item Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS -
Cog/11) ( Rosen 1984) ( Appendix 2). 
• Changes in scores on the Grooved Pegboard Test ( Lafayette 2002 ). 
• Changes  in scores on the Category Fluency Test (CFT) ( Acevedo 2000 ). 
• Changes in the Clinical Dementia Rating Scale – Sum of Boxes ( CDR -SOB ) (Hughes 1982 ) (Appendix 3). 
• Changes in the Alzheimer’s Disease Cooperative Study – Activities of Daily Living 23 (ADCS -ADL 23) 
(Galasko 1997) (Appendix 4 ). 
• Changes on the Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change (ADCS -
CGIC) (Ferris 1997) (Appendix 5). 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 19 of 100  
• Change on the Neuropsychi atric Inventory Questionnaire (NPI -Q) ( Kaufer 2000 ) (Appendix 6). 
• Change on the Savonix Neurocognitive Assessments and Digit Span  (Appendix 7). 
 
Secondary safety endpoints include:  
• Changes from baseline in clinical laboratory parameters.  
• Changes from baseline in vital sign measurements. 
• Changes from baseline in  the Columbia -Suicide Severity Rating Scale  (C-SSRS) (Posner 2011 )  
(Appendix 8). 
• Changes on MRI scans designed to assess for ARIA. 
 
Secondary feasibility endpoint s include:  
• Subject compliance with the study visit schedule, procedures, and infusions, and any required adaptations 
that are necessary for the study completion . 
• Success of blinding .  This  will be assessed based on all occurrences (intentional or unintentional) of 
unblinding of blinded study subjects, their trial partners or study personnel  (e.g. investigator s, medical 
providers, cognitive testing raters , the Sponsor or their representatives).  
 
4.2.3  EXPLORATORY ENDPOINTS  
 
The exploratory endpoint s include assessment of changes in composition and distribution  of blood-based and CSF 
(in consenting subjects) biomarkers, as well as changes in imaging results as measured by [CONTACT_746270], fMRI, and ASL .   
 
The serial compositional analysis of individual subject ’s plasma will be performed to identify specific biomarkers 
associated with cognitive functional changes and/or indicators of AD progression.  DNA will be extracted from blood samples to explore epi[INVESTIGATOR_14364].  In addition, subjects who consent to participate in the optional CSF 
biomarker research will undergo  two lumbar punctures for CSF collection, the first occurring prior to initial dosing, 
and the second occurring following final dosing.  The CSF will be utilized to assess the potential therapeutic effects 
of GRF6019 on AD biomarkers of neuronal death, synaptic function, inflammation, and growth factors.  [ADDRESS_1020730] meet the following criteria:  
• Male or female, aged 60-90 years (inclusive ). 
• Diagnos is of probable AD based upon the National Institute on Aging-Alzheimer’s Association (NIA-AA) 
Criteria. 
• MMSE Score 12 -24 inclusive . 
• Modified Hachinski Ischemia Scale (MHIS) score of ≤ 4 .   
• Have a dedicated, reliable and competent trial partner (e.g., caregiver or family member) who has frequent 
contact [CONTACT_1155]  (defined as approximately 10 hours per week) who is willing to provide support to the 
subject  to ensure compliance with stud y requirements .  The trial partner should understand the nature of the 
study and be willing to complete the trial partner  scales and functional assessments throughout the study . 
• The subject  (with support of a trial partner) must be able to follow the study  protocol, receive the treatmen t in 
the established timeframe, and continue during the follow -up interval .   
• The subject  and trial partner must be sufficiently fluent in English and have visual and auditory acuity sufficient 
to be capable of reliably completing all study assessments. 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 20 of 100  
• Provided a signed and dated informed consent form (either the subject and/or subject’s legal representative as 
well as the trial partner ) in accordance with local regulations/guidelines/IRB/IEC . 
• Adequate renal fun ction as defined by [CONTACT_10495] ( eGFR ) ≥ 45 mL/min/1.73 m2 using 
the Modification of Diet in Renal Disease (MDRD) study equation  (MDRD for Adults (Conventional Units) | 
NIDDK, n.d. ).  
• Systolic ejection fraction of ≥ 55% on trans -thoracic echocardiogram.  
• Willing to spend up to [ADDRESS_1020731] meet the following 
criteria:  
• Currently enrolled in the ALK6019-201 study. 
• Provided a  signed and dated informed consent form for CSF collection (either the  subject and/or subject’s legal 
representative) in accordance with local regulations/guidelines/IRB/IEC. 
• Not yet dosed in the ALK6019 -[ADDRESS_1020732] will not be eligible for inclusion if any of the following criteria apply : 
• Positive screening for Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) . 
• Evidence of clinically relevant neurological disorder(s) other than AD . 
• History of blood coagulation disorders or hypercoagulability; any concurrent use of an anticoagulant therapy.  (e.g., heparin, warfarin, thrombin inhibitors, Factor Xa inhibitors) .  Use of antiplatelet d rugs (e.g., aspi[INVESTIGATOR_167031]) is acceptable. 
• Initiation or change in the dosage of cholinesterase inhibitors (AChEI), memantine, Axona , vitamin E 
supplementation, or selegiline  within 3 months prior to screening.  
• Prior hypersensitivity reaction to any human blood product or intravenous infusion; any known clinically 
significant drug allergy.  
• Treatment with any human blood product, including transfusions and intravenous  immunoglobulin, during the 
6 months prior to screening.  
• History of immunoglobulin A (IgA), haptoglobulin or C1 inhibitor deficiency;  stroke, anaphylaxis, or 
thromboembolic complications of intravenous immunoglobulins.  
• Heart disease, including myocardial infarction, unstable , new onset or severe angina, or congestive heart 
failure ([LOCATION_001] Association Class II, III or IV) in the 6 months prior to dosing;  
• Poorly controlled high blood pressure (systolic blood pressure of 160 mmHg or higher and/or diastolic blood 
pressure of 100 mmHg or higher) despi[INVESTIGATOR_124483] 3 months prior to dosing, or treatment refractory high blood pressure, defined as treatment requiring  3 or more antihypertensives  from different 
classes. 
• History of Torsades de Pointes dysrhythmia or hypocalcemia of any kind, including secondary to absorption 
syndromes secondary to gastric by[CONTACT_4897]. 
• Current or chronic history of liver disease or known hepatic or biliary abnormalit ies (with the exception of 
Gilbert's syndrome or asymptomatic gallstones).  
• Uncontrolled diabetes defined as HbA1c > 7. 5% or requiring insulin . 
• Clinically significant abnormalities in complete blood count, com plete metabolic panel, serum albumin, serum 
lipi[INVESTIGATOR_805], b lood coagulation tests, or  the levels of thiamine, pyridoxine, cobalamin and thyroid stimulating 
hormone . 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 21 of 100  
• Hemoglobin <  10 g/dL in women and <  11 g/dL in men.  
• Urine protein -to-creatinine ratio (UPCR) of > 1.5 grams  of protein per gr am of creatinine . 
• Clinically significant abnormalities on screening electrocardiogram ( ECG) including QTc intervals (using 
Fridericia’s correction formula ) of ≥ 450 ms in men and ≥ 470 ms in wome n. 
• Clinically significant abnormalities on echocardiogram . 
• Inadequate venous access to allow IV drug delivery or multiple blood draws .  
• Concurrent participation in another interventional clinical trial.  Prior clinical trial subjects must have been off 
study agents for at least 30 days (or 5 half -lives, whichever is longer), 4 months for disease modifying 
therapi[INVESTIGATOR_014], and 1 year for vaccine or immunotherapy trials prior to screening.  
• Concurrent daily treatment with benzodiazepi[INVESTIGATOR_1651], long-acting opi[INVESTIGATOR_2438], or other medications that, in the 
investigator’s opi[INVESTIGATOR_1649], interfere with cognition.  [Note: intermittent treatment with low -dose s of shorter half -
life benzodiazepi[INVESTIGATOR_1651] (e.g. lorazepam, alprazolam)  may be permitted, provided that no dose is administered 
within the 72  hours preceding any cognitive assessment].  
• A history of a  major psychiatric disorder diagnosed before the onset of AD, in cluding schizophrenia , major 
depression or bipolar disorder, and/or alcohol/substance dependency.   Psychiatric symptoms that occur in the 
context of AD (e.g. psychosis,  irritability, depression) are not exclusionary unless the PI [INVESTIGATOR_746234].   
• Active suicidal ideation with at least some intent to act , with or without a specific plan, in the past 6 months . 
• Presence of a pacemaker or any other implant that would be a contraindication to an MRI exam  or 
claustrophobia  that would not enable the subject to undergo an MRI . 
• >2 lacunar strokes or other imaging abnormality on baseline MRI that would make the interpretation of  
subsequent  MRI scans of the brain  difficult.  
• Any other condition and/or situation that the investigator believes may interfere with the safety of the subject, 
the intent and conduct of the study, or interpretation of study data.  
A subject will not be eligible for inclusion in the optional CSF biomarker research if any of the following criteria 
apply : 
• Allergy or sensitivity to lidocaine or other local anesthetic s to be used for the lumbar puncture.  
• Skin infection near the site of the lumbar puncture.  
• Suspi[INVESTIGATOR_746235].  
• Suspi[INVESTIGATOR_746236] (e.g., as evidenced by [CONTACT_746271][INVESTIGATOR_044]). 
• Altered mental status (from baseline).  
• Use of oral antiplatelet therapy (e.g. clopi[INVESTIGATOR_7745], prasugrel, ticagrel) within [ADDRESS_1020733] enrollment in this trial to be consistent with the observation that typi[INVESTIGATOR_746237] -Hispanic whites.  If the risk/benefit analysis of GRF6019 justifies 
larger subsequent trials, special efforts will be made to enroll subjects from diverse ethnic and racial groups. 
 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020734]’s agreement to participate in the study will still be obtained to their best level of 
his or her understanding, and recruitment will not proceed if the subject  refuses, shows significant distress or the trial 
partner and/or legally authorized representative refuse .  For subjects who are, in the opi[INVESTIGATOR_871], unable to 
give in formed consent , consent will be obtained from the legally authorized representative.  Subjects  will receive a 
modest stipend for participation in the study.  
 
The expected length of participation in the study, seven months, is not expected to be unduly onerous on subjects or their 
trial partners.  During the two treatment periods at weeks 1 and 13 , subjects will be housed in inpatient clinical trial units.  
If the trial partner do es not reside within a reasonable distance from the inpatient facility, they will be given the option to 
stay with the subjects or to stay in a nearby [CONTACT_746272]/motel .  Financial support  for meal  and miscellaneous expenses may be 
provided as appropriate (it is expected that meals will be provided by [CONTACT_746273] ).  Use of visit 
transport services and study buddies (registered and trained personnel that can stand in for the trial partner for required visits) ma y also be incorporated into the trial to support both the subject and their trial partner in maintaining study visit 
compliance.  
 A description of the clinical trial will be posted on clinicaltrials.gov  that will provide additional transparency to the 
public and possibl y aid study  recruitment .  In addition,  advocacy groups and patient networks will be approached for 
recruitment as needed . 
 
5.[ADDRESS_1020735] will be  withdrawn from  the study for the following medical or administrative reasons:  
• Occurrence of a treatment-emergent AE that represents an unacceptable risk to the subject and 
when continued participation in the investigational study is not warranted, in the judgment of the 
investigator .  The investigator must follow the subject until the AE resolves or is stable, unless the 
subject is lost to follow up . 
• Subject and/or trial partner  noncompliance, defined as refusal or inability to adhere to the trial 
schedul e or procedures.   
• At the request of the subject or the subject’s legally authorized representative (e.g., subject  
withdraws consent), investigator, Sponsor , or regulatory authority. 
• Pregnancy . 
 
5.4.2  HANDLING OF PARTIC IPANT WITHDRAWALS OR TERMINATION   
 
Subjects will be encouraged to complete the study and all assessments.  However, subjects may voluntarily withdraw 
at any time, and the investigator ma y discontinue individual subjects from the study at any time .   
 
Approximately 40 subjects (approximately 20 in the 100 mL  group and 20 in the 250 mL  group ) will be enrolled in 
the study with the intent of obtaining at least [ADDRESS_1020736] -study AE and SAE reporting, see 
Section 8.3.1 .  The primary reason for study discontinuation will be documented on the case report form (CRF).  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 23 of 100  
 
5.5 PREMATURE TERMINATION OR SUSPENSION OF STUDY  
 
The Sponsor reserves the right to terminate the study at any time.  Should this be necessary, the Sponsor and/or their 
representatives will arrange discontinuation procedures and notify the appropriate regulatory authority(ies) and IRBs.  In terminating the study, the Sponsor and the investigator will continue to protect t he subjects’ privacy and identity as 
required by [CONTACT_167063].  
 
Alkahest, Inc. has the right to terminate a study site from participating in the study at any time. Reasons for study or site  
termination may include, but are not limited to:
 
• (Immediate) risk to subject safety.  
• Unsatisfactory subject enrollment.  
• Unacceptable Protocol Deviations  as assessed  by [CONTACT_2728] . 
• Inaccurate or incomplete data entry and recording; fabricated data.  
• Investigational site non-compliance with ICH/GCP . 
• Unacceptable emergent safety profile.  
 
6 STUDY AGENT 
6.1 STUDY AGENT(S) AND CONTROL  DESCRIPTION   
 
6.1.1  ACQUISITION  
 
The study agent will be commercially manufactured  by [CONTACT_746274], N orth Carolina  facility in 
accordance with license BL 101140.  The material will be supplied to the sites directly from a study drug depot .   
 
6.1.2  FORMULATION, APPEARANCE, PACKAGING, AND LABELING  
 
 
 
 
 
 
 
   
GR
F6019 will be supplied in 250 mL glass vials  bearing a label that meets applicable regulations  for investigational 
protein products  (further manufactured) per 21 CFR 312.6.  The label will clearly identify the study agent and 
manufacturer, and will display other required information specifically applicable to its intended use, including but 
not limited to: 
• Federal law statement 
• Storage information  
• Volume (accurate within ± 10%)  
• Expi[INVESTIGATOR_746238]# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020737] STORAGE AND STABILITY 
 
The study agent should be stored at  room temperature not exceeding 30°C (86°F ).  Solution that has been frozen 
should not be used.  Do not use after expi[INVESTIGATOR_320].  
 
Solutions which are turbid should not be used.  A dministration of the study agent must begin within [ADDRESS_1020738] allowed the entry of microorganisms .     
 
6.1.4  PREPARATION  
 The study agent is compatible with the usual carbohydrate and electrolyte solutions .  Remove seal to expose stopper .  
Always swab stopper top immediately with suitable antiseptic prior to entering the vial.  
 Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit .   
 Only 16-gauge  (or larger) needles or dispensing pi[INVESTIGATOR_746239] [ADDRESS_1020739]  (or other qualified 
personnel responsible for drug accountability)  to an unblinded Infusion Nurse .  Administration of the study agent 
will be perfor med by [CONTACT_179114], and study outcome measures (including AEs  and vital signs ) 
will be assessed by a blinded Outcomes Assessor .   
 
Infusion Nurses will be qualified by [CONTACT_179115] .  Only authorized Infusion Nurses  may administer the study agent , and only subjects enrolled 
in the study may receive the study agent  in accordance with applicable regulatory requirements.  
 
6.1.6  ROUTE OF ADMINISTRATION  
 
The study agent will be administered by [CONTACT_167066].  
  

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020740]  and their trial partner  is ~[ADDRESS_1020741]  or other qualified personnel  is 
responsible for ensuring adequate accountability of all used and unused study agent .  This includes acknowledgment of 
receipt of each shipment of stud y agent (quantity and condition), subject dispensing records, and returned or destroyed 
study agent.  Dispensing records will document quantities received and quantities dispensed to subject s including the  
date dispensed, the intended subject ’s study  identifier , the initials of the individual responsible for  dispensing  the study 
agent,  and the initials of the Infusion Nurse administering the study agent .  Drug accountability will be monitored by [CONTACT_746275].  
 
Accountability records  must be maintained and readily available for inspection by [CONTACT_124524], Inc. or 
their designee and are open to inspection by [CONTACT_108889] .  The accounts of any study agent  
accidentally wasted or intentionally disposed of must be maintained .   
 The disposal of used, partially used, or wasted study agent must be performed in accordance with the institution’s drug 
disposal policy.  At study initiation, the clinical study monitor will evaluate the site’s standard operating procedure for 
study drug disposal/destruction in order to ensure that it complies with study requirements .  At the end of the study, 
following final drug reconciliation by [CONTACT_2037], the study site will be instructed by [CONTACT_746276], including empty containers .  A copy of the institution’s drug disposal policy should be 
maintained or referenced in the site’s r egulatory binder . 
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 26 of 100  
7 STUDY PROCEDURES AND SCHEDULE  
7.1 STUDY PROCEDURES/EVALUATIONS  
7.1.1  STUDY SPECIFIC PROCED URES 
 
[IP_ADDRESS] Screening Procedures  
During screening, the  following will be performed:  
• C-SSRS 
• Assessment of probable AD including MMSE  
• MHIS  
• Medical h istory  
• Demographics  
• Review of m edications 
• Vital signs 
• Physical examination 
• 12-Lead ECG 
• Blood and urine collection for laboratory e valuations  
• Echocardiogram * 
• MRI* 
• PET Scan (optional; to be performed after all screening procedures have been completed, and the subject 
meets criteria for inclusion )  
 
*Note: the  echocardiogram  and screening MRI should be performed after all other screening procedures have been 
completed, and the subject meets all  other criteria for inclusion.  The echocardiogram  and screening MRI may be 
completed in any order .  
 
Detailed descriptions of each of these procedures are provided in the sections immediately following .  Information 
pertaining to all study activities performed during screening, and the sequence of events, is provided in Section 7.3.1 
Screening . 
 
[IP_ADDRESS].1 Columbia -Suicide Severity Rating Scale  
The C-SSRS is a simple series of questions for the assessment of suicidal ideation and behavior in clinical trials 
(Posner 2011 ) (Appendix 8 ).  The C -SSRS was designed to distinguish the domains of suicidal ideation and suicidal 
behavior in subjects who have expressed  wishes to be dead or suicidal thoughts .  Four constructs are measured .  The 
first is the severity of ideation, which is rated on a 5 -point ordinal scale in which 1=wish to be dead, 2=nonspecific 
active suicidal thoughts, 3=suicidal thoughts with methods, 4=suicidal intent, and 5=suicidal intent with plan.  The second is the intensity of  ideation subscale, which comprises 5 items, each rated on a 5 -point ordinal scale: 
frequency, duration, controllability, deterrents, and reason for ideation.  The third is the behavior subscale, which is rated on a nominal scale that includes actual, aborted, and interrupted attempts; preparatory behavior; and non-suicidal self -injurious behavior .  And the fourth is the lethality subsca le, which assesses actual attempts; actual 
lethality is rated on a 6 -point ordinal scale, and if actual lethality is zero, potential lethality of attempts is rated on a 
3-point ordinal scale .  The use of a standardized measure such as the C -SSRS comprehensively assesses suicidal 
behavior and ideation.  
 
The C-SSRS will be administered by [CONTACT_746277]# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020742]’s lifetime and in the past [ADDRESS_1020743]’s last C -SSRS assessment.     
 
[IP_ADDRESS].2 Assessment of Probable Alzheimer’s Disease 
Subjects will undergo an assessment for AD using NIA-AA criteria ( McKhann 2011 ).  Probable AD is diagnosed 
when the subject meets criteria for dementia per MMSE score (12 -24 inclusive)  (Refer to Section [IP_ADDRESS].3 ), and in 
addition, has the foll owing characteristics:  
• Insidious onset .  Symptoms have a gradual onset over months to years, not sudden over hours or days;  
• Clear -cut history of worsening of cognition by [CONTACT_124526]; and  
• The initial and most prominent cognitive deficits are evident on history and examination in one of the 
following categories:  
o Amnestic presentation: It is the most common syndromic presentation of AD .  The deficits 
should include impairment in learning and recall of recently learned information.  There should 
also be evidence of cognitive dysfunction in at least one other cognitive domain, as defined 
earlier in the text.   
o Nonamnestic presentations:  
1. Language presentation: The most prominent deficits are in word -finding, but deficits in 
other cognitive domains should be present .   
2. Visuospatial presentation: The most prominent deficits are in spatial cognition, including object agnosia, impaired face recognition, simultanagnosia, and alexia .  Deficits in other 
cognitive domains should be present .   
3. Executive dysfunction: The most prominent deficits are impaired reasoning, judgment, and problem solving.  Deficits in other cognitive domains should be present .   
 The diagnosis of probable AD should not be applied when there is evidence of one or more of the following:  
• Substantial concomitant cerebrovascular disease defined by a history of a stroke temporally related to the 
onset or worsen ing of cognitive impairment . 
• The presence of multiple or extensive infarcts or severe white m atter hyperintensity burden. 
• Core features of dementia with Lewy bodies other than dementia itself. 
• Prominent features of behavioral variant frontotemporal dementia . 
• Prominent features of semantic variant primary progressive aphasia or non -fluent/agrammatic variant 
primary progressive apha sia. 
• Evidence for another concurrent, active neurological disease, or a non-neurological medical comorbidity 
or use of medication that could have a substantial effect on cognition.  
 Previous radiologic imaging and/or  assessment of AD CSF  biomarkers will be collected, if available, to support the 
clinical diagnosis of AD.  Amyloid imaging by [CONTACT_340662] (PET)  performed within 12 months 
of screening  will be used , if available, to estimate beta-amyloid neuritic plaque density at baseline (See 
Section 
[IP_ADDRESS] ). 
 
[IP_ADDRESS].3 Mini -Mental Status Examination  
The MMSE (Folstein 1975 ) (Appendix 1) consists of the following 5 components: orientation to time and place (2 
items), registration of 3 words (1 item), attention and calculation (1 item), recall of 3 words (1 item), and language (6 items) .  The scores from the [ADDRESS_1020744] has 1 missing item, the following algorithm will be used to compute the total score: Total score = [(total 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 28 of 100  
score from completed items) / (maximum total score for completed items)] x (maximum total score [=30] for all 
items in the scale) .  The total score is then rounded to the next highest integer .   
 If there is more than 1 missing item, the total score will be considered missing at that time point .  The MMSE total 
score can range from 0 to 30, with higher scores indicating better mental status .  Change scores will not be calculated 
for the individual items .   
 
[IP_ADDRESS].4 Modified Hachinski Isc hemic Scale  
The MHIS ( Rosen 1980
) is an [ADDRESS_1020745] a dementia of vascular 
etiology and thus  are excluded from participating in the trial.  
 
[IP_ADDRESS].[ADDRESS_1020746]’s trial partner during screening .  The medical history should focus on recent history, with an emphasis on the 
history of cognitive symptoms related to probable AD .  Additionally, the medical history should include:  
• Current/past illnesses and conditions  
• Current symptoms 
• Surgeries and procedures  
• Allergies  
• Family history  
• Social history (e.g. exercise, smoking, alcohol, illegal substances) and current living situation  
• Cause of parental death (if not living)  
• Prior radiologic imaging, CSF assessments, and/or PET Scan results (if available  and within 12 months  of 
screening) 
 
[IP_ADDRESS].[ADDRESS_1020747]’s socioeconomic status ( e.g. highest level of income  achieved , education, 
longest held occupation) , ethnicity, race, marital status, and family size will be collected by [CONTACT_746278]’s trial partner at screening.  
 
[IP_ADDRESS].[ADDRESS_1020748]’s current medications, including over -the-
counter drugs, herbal supplements and/or vitamins, as well as those taken by [CONTACT_124527] 12 months .  
Assessment of eligibility should include a review of permitted and prohibited  medications.  Any additions,  
discontinuation or dosage changes in medication during the course of the study will be recorded.  
 
[IP_ADDRESS].8 Vital Signs  
Vital signs will include seated systolic and diastolic blood pressure (mmHg), heart rate (beats per minute [bpm]), 
respi[INVESTIGATOR_1487] (breaths per minute), and oral temperature.  Vital signs will be measured after the subject has been 
seated for 5 minutes.  
 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 29 of 100  
[IP_ADDRESS].9 Physical Examination  
A full physical examination will be performed to assess the following organ systems: skin, ENT (ears, nose, and 
throat), head, eyes, lungs/chest, heart, abdomen, musculoskeletal, extremities, neurologic  and lymphatic  systems.  
Height and weight will also be documented.  
 
[IP_ADDRESS]. [ADDRESS_1020749] 5 minutes in a supi[INVESTIGATOR_2547] .  In 
some cases, it may be appropriate to repeat abnormal ECGs to rule out technical factors contributing to ECG artifacts 
or abnormality.  It is  important that leads are placed in the same positions each time for consistency .  The overall 
conclusion with the interpretation of the ECGs will be recorded on the appropriate CRF .  The interpretation of the 
ECGs will be recorded as normal, abnormal but not clinically significant ( NCS ), or abnormal and clinically 
significant ( CS).  Corrected QT c intervals will be calculated using Fridericia ’s correction  formula .   
 
[IP_ADDRESS].[ADDRESS_1020750]’s left ventricular (LV) systolic function to ensure the subject’s ejection fraction is ≥ 55% (Gebhard 2012
).   
 
[IP_ADDRESS].1 2 Biological Specime n Collection  
Biological samples will be obtained, analyzed , and stored appropriately for additional analysis .  Blood and CSF (in 
partici pating subjects) will be drawn by a qualified medical provider, and urine specimens will also be col lected .  
These samples may be used for re-testing, further evaluation of an AE and/or assessment , and follow -up of other 
exploratory endpoints .  The timing and frequency for specimen collection and laboratory evaluations to be performed 
are described in  the study’s laboratory manual  and Section 17 Schedule of Events . 
 
Samples that remain after study testing is complete will be stored in the event additional testing (e.g., further evaluation of an AE or assessment of effect) is required .  Samples will be stored in a deidentified coded for m.   
 
[IP_ADDRESS].[ADDRESS_1020751] has met all other inclusion criteria and none of the 
exclusion criteria (except  the echocardiogram, which can be performed before or after the MRI).  The sequence may 
also include vMRI, fMRI, and /or ASL.  Additional information is provided in Section [IP_ADDRESS]
. 
 
[IP_ADDRESS] Procedures to Assess Safety 
Subjects enrolled in the trial will be monitored closely to assess safety and tolerability of the study agent and intervention.  Study -specific procedures that will be used for this purpose are summarized below.  Information 
regarding the timing and frequency of these procedures is provided in Section 7.3 Study Schedule
.   
• Review of AEs 
• Review of medications 
• Vital signs  
• C-SSRS 
• 12-Lead ECGs 
• Targeted physical exams  
• End of Study  (or Early Termination) Physical Examination  
• Blood Draw and Urine Collection for Laboratory Evaluations  
• MRI to assess for ARIA  
 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 30 of 100  
[IP_ADDRESS].1 Review of Adverse Events  
AEs will be reviewed, d ocumented, and reported as requir ed at each visit .  For definitions, guidance, and additional 
information regarding AEs, refer to Section 8 .   
 
[IP_ADDRESS].[ADDRESS_1020752]’s current medications, including over -the-counter drugs, 
herbal supplements and/or vitamins, as well as those taken by [CONTACT_124528] .  Changes to the 
subject’s list of medications should be reviewed and recorded .  Review of medications should occur at every visit.  
 
[IP_ADDRESS].3 Vital Signs  
Refer to Section [IP_ADDRESS].8  for a description of Vital Signs .  Vital Signs will be collected at every visit.  During 
infusions, vital signs will be collected according to the  Infusion Administration Manual by [CONTACT_179120] .    
 
[IP_ADDRESS].4 Columbia -Suicide Severity Rating Scale  
Refer to Section [IP_ADDRESS]. 1 for a description of the C -SSRS.  
 [IP_ADDRESS].5  12-Lead ECG  
Refer to Section [IP_ADDRESS].10
 for information pertaining to 12-Lead ECGs.  
 [IP_ADDRESS].[ADDRESS_1020753] is inpatient, a targeted physical exam, including auscultation of the heart and lungs , an assessment 
of peripheral edema, and weight , will be performed per the Study Schedule ( Section 7.3
).   
 
[IP_ADDRESS].7 Physical Exam  
Refer to Section [IP_ADDRESS].9  for a description of the physical exam.  The physical exam, including measurements of 
height and weight, will be  performed at screening and  repeated at End of Study  (or early termination) .   
 
[IP_ADDRESS].8 Blood and Urine Collection for Laboratory Evaluations  
As described in Section [IP_ADDRESS].[ADDRESS_1020754] blood and urine specimens collected for clinical evaluation 
(Section 7.2.1 Clinical Laboratory Evaluations ).  Refer to Section 17 Schedule of Events  for timing and frequency of 
blood and urine collection for laboratory evaluations .   
 
[IP_ADDRESS] Procedures to Assess Efficacy  
Procedures to assess efficacy include neuropsychological and motor function testing and radiologic imaging.  
Information regarding the timing and frequency of these procedures is provided in 7.[ADDRESS_1020755]’s participation unless a change in rater is unavoidable.  
The established order of behavioral and cognitive testing during visits with multiple assessments will be  as follows 
(unless otherwise specified) :  
 
1. C-SSRS* (refer to Section 7.1.1 .1.1)  
2. MMSE * (refer to Section [IP_ADDRESS].3 ) 
3. Savonix Neurocognitive Assessments and Digit Span   
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 31 of 100  
4. ADAS -Cog /[ADDRESS_1020756] -SOB  (subject and trial partner) 
8. ADCS -ADL 23 (trial partner) 
9. ADCS -CGIC (subject  and trial partner )  
10. NPI-Q (trial partner self -administered ). Note: The trial partner may  complete the NPI -Q at any available 
time during applicable visits  
 
Assessments with an asterisk (*) should only be performed during follow -up when required per protocol. 
Descriptions of each neuropsychological and motor function assessme nt are provided below.  
 
[IP_ADDRESS].[ADDRESS_1020757]  (HIPAA)  compliant computer -based application for iOS or Android devices that integrates 
multiple aspects of common neurocognitive tests into one computerized assessment.  Measured elements across brain 
domains include instant verbal memory, delayed verbal memory, impulse control, focus, attention, emotional 
regulation, emotion identification, information processing, flexible thinking, working memory, executive function, 
spatial memo ry, decision making, and emotionality ( Appendix 7 ).   
 
Assessments using a digital interface are expected to provide more granular neurocognitive data while at the same time being less burdensome to the subject .  This pi[INVESTIGATOR_746240].   
.   
Subjects will be provided instructions and asked to complete either a full or brief battery at every study visit, starting 
at baseline.  The full battery of tests includes the Savonix-8 and Digit Span (forwards and backwards) and takes 
approximately 30-40 minutes to complete.  The Savonix -8 consists of:  
• Verbal Memory – immediate and delayed  
• Go/No-Go 
• Verbal Interference  
• Complex Figure Copy  
• N-back  
• Maze Task  
• Emotion Identification Task 
• Trails A and B  
 
The brief battery will be administered d uring infusion visits  and should be  completed prior to starting the infusion.  
The brief battery takes approximately 15 -20 minutes to complete and consists of:  
• Go/No -Go 
• Color Interference  
• N-back  
• Trail-Making tasks  
• Digit Span  
 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 32 of 100  
[IP_ADDRESS].2 The Alzheimer’s Disease Assessment Scale – Cognitive Subscale 
The ADAS -Cog/11 ( Rosen 1984) (Appendix 2 ) includes 11 items assessing cognitive function ( Skinner 2012 ).  The 
domains include memory, language, praxis, and orientation.  There are [ADDRESS_1020758] performance is assessed for errors in following 
ordered commands, naming of real objects and of fingers, constructional praxis (copying of geometr ic forms), 
ideational praxis (preparation of a letter for mailing), orientation, a 10-item word recall task and a [ADDRESS_1020759] greater cognitive impairment .  Individual testing domains may be 
separated out for the purposes of statistical analysis.  
 
[IP_ADDRESS].[ADDRESS_1020760] measuring visual -motor coordination ( Lafayette 2002 ).  The 
test consists of a pegboard with  [ADDRESS_1020761] to complete the task.  
 
[IP_ADDRESS].[ADDRESS_1020762] 
responses for the pooled categories ( Acevedo 2000
). 
 
[IP_ADDRESS].5 Clinical Dementia Rating Scale – Sum of Boxes  
The Clinical Dementia Rating Scale (CDR) is a global assessment instrument that yields global and sum of boxes 
(SOB) scores, with the global score regularly used in clinical and research  settings to stage dementia severity .  The  
CDR is obtained via semi -structured interviews with patients and informants (e.g. trial partners)  to characterize 
functioning in 6 domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care (
Hughes 1982 ).  Each domain is rated on a [ADDRESS_1020763] score in patients with mild 
dementia ( O’Bryant 2008) (Appendix 3 ).  Individual testing domains may be separated out for the purposes of 
statistical analysis.  
 
[IP_ADDRESS].6 A lzheimer’s Disease Cooperative Study Group – Activities of Daily Living 23  
The ADCS -ADL 23 assesses the competence of patients with AD in performing basic and instrumental activities of 
daily living.  The ADCS -ADL 23 contains 23 items covering physical and mental functioning and independence in 
self-care.  For each activity of daily living (ADL) , an informant  (e.g., trial partner) is first asked if the patient 
attempted the activity during the past 4 weeks .  If a patient did attempt the ADL, the informant (e.g., trial partner ) is 
asked to choose the single most accurate definition of the patient’s level of performance .  The scores range from 0 to 
78, with higher scores indicating less functional impairment  (Galasko 1997) (Appendix 4 ). 
 [IP_ADDRESS].7 Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change  
The ADCS -CGIC is a systematic method for assessing clinically significant change in a clinical trial as viewed by [CONTACT_746279] ( Ferris 1997 , Schneider 1997) ( Appendix 5
).  The ADCS -CGIC 
focuses on clinicians' observations of change in the subject's cognitive, functional, and behavioral perform ance since 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020764] and interview of informants (e.g. trial 
partner). 
 
[IP_ADDRESS].[ADDRESS_1020765] ations of dementia and determines their frequency 
and intensity ( Kaufer 2000 ) (Appendix 6).  It is designed to be a self -administered questionnaire completed by 
[CONTACT_746280] (e.g. trial partners) about subjects for whom they care.  Generally, the NPI -Q is used to evaluate changes 
in subject behavior that have appeared during a given period.   
 
The NPI -Q comprises 12 domains: delusions, hallucinations, dysphoria, apathy, euphoria, disinhibition, aggressivity 
and restlessness, irritability, anxiety, aberrant motor behavior, appetite and eating disorders, and nocturnal behavior .  
Initial responses to each domain question are "Yes" (present) or "No" (absent) .  If the response to the domain 
question is "No", the informant goes to the next question.  If "Yes", the informant then rates both the severity of the 
symptoms present within the last month on a 3-point scale and the associated impact of the symptom manifestations 
on them (i.e., trial partner distress) using a 5 -point scale.  Thus, the NPI-Q evaluates response to therapy and 
provides symptom severity and distress ratings for each symptom reported, and total severity and distress scores reflecting the sum of individual domain scores.  
 
7.2 LABORATORY PROCEDURES/EVALUATIONS  
 
7.2.1  CLINICAL LABORATORY EVALUATIONS  
 
Biological samples (e.g. whole blood, serum, urine)  will be collected  for laboratory evaluations  in accordance 
with the Schedule of Events ( Section  17).  Clinical sample processing and laboratory evaluations will be 
conducted by a central lab’s registered and certified Clinical Laboratory Improvement Amendments (CLIA) 
facilities.  STAT laboratory evaluations will be conducted at the clinical site.  Refer to the  study’s  laboratory 
manual for complete information regarding all laboratory eval uatio ns to be performed, sample collection 
procedures, and related requirements.  
 
The investigator is responsible for determining and documenting if out of range laboratory values are clinically 
significant or not .  All clinically significant values will be rec orded as AEs in the CRF and followed until 
resolution , unless the subject is lost to follow up.  Once resolved, the appropriate CRF page(s) will be updated .   
 
7.2.2  OTHER ASSAYS OR PROCEDURES  
 
[IP_ADDRESS]  Apolipoprotein E (ApoE) Genotype Testing   
ApoE genotype  is a known risk factor  for AD pathogenesis, with presence of the ApoE ε4 allele carrying increased 
risk.  This risk is further influenced by [CONTACT_654], sex, race, and ethnicity .  Thus, determining ApoE genotype a t baseline 
will allow for the assessment of possible differential effects of ApoE genotype on safety, treatment efficacy, neuroimaging and other exploratory measures .   
 
[IP_ADDRESS] P ositron Emission Tomography (Optional)  
Documented PET Scan is optional and not required for inclusion in the study .   
 Subjects who have had a  PET Scan using any radioligand within 12 months  of screening will be asked to provide 
copi[INVESTIGATOR_746241] .  The historical scan will be used to estimate the density of beta-amyloid neuritic 
plaque.  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020766] .   
 [IP_ADDRESS]  Magnetic Resonance Imaging  
MRI [3 T esla (T)  preferred but 1.5T will be accepted ] will be used to evaluate subjects’ eligibility for inclusion in the 
study and to assess safety  (ARIA) at Visit 8.  MRI may also be used  to compare neural activity and brain atrophy at 
screening/baseline, after the first series of pulsed doses, and at  end of study.  During the MRI, the subject will be 
asked to lie on a narrow bed in a large tunnel while images are cap tured by [CONTACT_179128].  The screening and 
Visit 8 scans will be interpreted by [CONTACT_746281].  The 
MR images may also be analyzed centrally at the end of the study  by [CONTACT_347913].  
 
The MRI exam after dosing on Visit 8 will be used to evaluate subjects for possible ARIA.  ARIA are MRI 
abnormalities, including signa l changes thought to represent vasogenic edema and/or  microhemorrhages that have 
been seen in subjects enrolled in  clinical trials of  experimental amyloid-modifying therapi[INVESTIGATOR_014] .   
 
 
[IP_ADDRESS]  Proteomic and Genetic Biobanking  
Blood and plasma will be collected from subjects at multiple timepoints throughout the trial for biobanking.  For 
information regarding the timing and procedures for sample collection and related requirements, refer to the study’ s 
laboratory m anual and Section [ADDRESS_1020767] overview of the proteins that are present in the plasma sample 
by [CONTACT_58833] 1000- 5000 analytes and allow generation of a proteomic signature .  From this signature, we hope to 
identify key proteins that are drivers of cognitive function and/or indicators of disease progression.  Blood  samples 
will be retained for analysis of emergent genetic markers of disease .  By [CONTACT_746282], we seek to identify the biomarkers relevant to further optimizing treatment in AD.  For information regarding future use of stored samples , see Section 12.5 Future Use of Stored Specimens
. 
 [IP_ADDRESS] Cerebrospi[INVESTIGATOR_746242] (Optional)  
Participation in the cerebrospi[INVESTIGATOR_872] (CSF) biomarker research is optional and not required for inclusion in the study.  
 
The CSF collection procedure, as well as the potential risks and benefits, will be explained to all study participants  at 
participa ting s ites.  Subjects who are eligible and consent to participate will undergo two lumbar punctures for CSF 
collection, the first occurring prior to initial dosing, and the second occurring following final dosing.  If a subject 
withdraws from the study ear ly but is willing to provide the second (final) CSF sample, this can be obtained as long 
as the subject received at least two infusions of GRF6019.   If the subject is currently taking antiplatelet therapy (e.g. 
clopi[INVESTIGATOR_7745], prasugrel, ticagrel), this medic ation must be withheld for 5 days prior to each lumbar puncture 
(treatment with aspi[INVESTIGATOR_746243]).  
 
The lumbar punctures  should be performed by a physician experienced in the procedure  and according to the site’s 
standard procedures.   Both lumbar punctures  should be performed at approximately the same time of day and the 
time should be recorded.  For each lumbar puncture , 12-15 mL of CSF will be collected by [CONTACT_20138] (not aspi[INVESTIGATOR_1516]). 

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020768] 75% filled, and the number of aliquots should be adjusted 
to achieve this (depending on the final CSF volume collected).  
 
CSF aliquots will be thawed and analyzed for specific AD biomarker assessments including  
.  CSF samples will also be analyzed by [CONTACT_746283]6019 infusions.  These methodologies will provide a broad overview of the proteins that are present in the CSF samples and allow generation of a proteomic signature.  From this signature, we 
hope to identify key proteins that are drivers of cognitive function and/or indicators of disease progression.  For 
information regarding future use of stored samples, see Section 12.5 Future Use of Stored Specimens
. 
 
7.2.3  SPECIMEN PREPARATION, HANDLING, STORAGE , AND SHIPPI[INVESTIGATOR_179093]’s  laboratory manual  for specimen preparation, handling, storage , and shippi[INVESTIGATOR_4585] .   
 
7.3 STUDY SCHEDULE  
 
Visit windows  (when noted) should be benchmarked relative to Visit [ADDRESS_1020769], such that subjects complete the 
entire study  by [CONTACT_2006] 168 (±7 days) .  Study visit procedures are listed in the recommended order in which they should 
be completed .   
 
7.3.1  SCREENING 
 
Visit  1, Screening  (Day -28 to -8) 
□ Informed consent of subject (and/or the subject’s legally authorized representative) and the subject’s trial partner  must be obtained prior to  any study -related assessments  
□ Administer  the C-SSRS  
□ Assess for probable AD using NIA-AA criteria including MMSE  
□ Conduct the  MHIS   
□ Obtain medical history , including medical records to support AD diagnosis if available  
□ Collect demographic information 
□ Review subject’s current and prior medications 
□ Review and provide the subject (and subject’s trial partner) with a list of permitted and prohibited 
medications  
□ Collect vital signs, height, and weight  
□ Perform the physical exam  
□ Perform 12-Lead ECG  
□ Collect  specimens for the laboratory panel  
□ Perform transthoracic echocardiogram  
□ Complete MRI  
□ Complete PET Imaging (optional )  

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 36 of 100  
 
Note: T he Screening Visit may be split to allow for sufficient time to  complete all required procedures.  AEs and 
concomitant medications should be collected  during split visits, as applicable.  Any PET Imaging should be 
completed after the MRI but before Visit 3.  The optional PET scan should only be performed after the subject 
has met criteria for inclusion in the study . 
 
7.3.2  BASELINE  
 
Visit 2, Baseline  (Days -7 to -1) 
□ Re-review screening assessments for eligibility (e.g., MMSE scores, lab values) 
□ Review AEs and concomitant medications 
□ Collect the following:  
o Vital signs  
o Samples for proteomics/epi[INVESTIGATOR_7009]/biobanking (fasting samples are preferred ) 
o Buccal swab for ApoE Genotype testing  
□ Ensure the subject has had an opportunity to eat a meal prior to commencing cognitive and motor testing  
□ Perform cognitive and motor testing in the following order  unless otherwise specified : 
1. Savonix Full Battery  
2. ADAS -Cog/[ADDRESS_1020770] -SOB (subject and trial partner)  
6. ADCS -ADL 23 (trial partner) 
7. ADCS -CGIC (subject  and trial partner)  
8. NPI-Q (trial partner self -administered ; may be completed by [CONTACT_746284] ) 
□ Confirm subject  eligibility prior to initiating treatment  
□ In consenting, eligible subjects, perform initial lumbar puncture and obtain CSF samples for optional 
biomarker research .  
 
Note: The Baseline Visit may be split to allow collection of all required assessments.  
 
7.3.[ADDRESS_1020771] dose on Visit 3.  
Subjects who are randomized but do not receive any dose of the study agent, may be re-screened and randomized if 
they meet all of the study eligibility requirements.  
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 37 of 100  
7.3.4 TREATMENT 
 
There are two inpatient treatment periods scheduled during the trial, each with a total of 5 infusions .  It is anticipated 
that sites will infuse subjects with 5 doses over 5 days.  A “grace day” is allowed in the event of unanticipated safety 
or health concerns during each inpatient treatment period.  
 
Visits 3-7 (Days 1- 5) and 11 -15 (Days 85*-89): 
*Day 85 has a ± 7-day  window.  Visits 12 -16 should follow consecutively.   
□ Perform the following procedures prior to administering study treatment:  
o Review AEs and concomitant medication s 
o Obtain  blood and urine samples for comprehensive laboratory panel ; fasting samples preferred  
(Visits 4, 6, 12 , and 14 Only ) 
o Obtain samples for proteomic s/epi[INVESTIGATOR_7009]/biobanking; fasting samples preferred (Visits 3 and 11 
Only ) 
o Obtain i-STAT safety laboratory test samples and assess results before each infusion  
o Perform targeted physical exam (i.e. auscultation of heart and lungs and assessment of peripheral  
edema)  
o Measure and record the subject’s weight in kilograms 
o Perform 12 -lead ECG ( Visit 11 Only ) 
o Ensure  the subject has had an opportunity to eat a meal prior to cognitive and motor  testing  
o Administer the Savonix Brief Battery  
o Perform ADAS -Cog/11 ( Visit 11 Only ) 
o Collect pre-infusion vital signs   
□ Administer study treatment  and perform safety assessments per the Infusion Administration Manual  
□ Post-infusion:  perform 12 -lead ECG ( Visits 7 and 15 Only ) 
 
7.3.5 FOLLOW-UP  
 
Visits 8 and 16 (Day 6 and Day 90 – Last Day of Inpatient Stay): 
□ Review AEs and concomitant medications 
□ Collect the following:  
o Vital signs and subject’s weight in kilograms 
o Blood and urine samples for comprehensive laboratory panel  (fasting samples preferred ) 
o Samples for proteomics/epi[INVESTIGATOR_7009]/biobanking (fasting samples preferred ) 
o i-STAT safety  laboratory test samples and assess results before discharge  
□ Perform targeted physical exam (i.e. auscultation of heart and lungs and assessment of peripheral  edema)  
□ Ensure  the subject has had an opportunity to eat a meal prior to cognitive and motor  testing  
□ Perform cogn itive assessments in the following order :  
1. C-SSRS 
2. MMSE  
3. Savonix Full Battery  
4. ADAS -Cog/11 
□ Complete MRI  (Visit 8  + 4 days  Only) 
□ In consenting, eligible subjects, perform final lumbar puncture (after final dosing) and obtain CSF samples 
for optional biomarker research ( Visit 16 or within 5 days following ) 
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 38 of 100  
Visit 9  (Day 28 ±7 days) and Visit 17 (Day 112 ±7 days) 
□ Review AEs and concomitant medications 
□ Collect the following:  
o Vital signs  
o Blood samples for interim safety labs (Note: S ubjects randomized prior to August 30, 2018, will not 
participate in the additional interim safety labs at Visit 9 and Visit 17 .) 
o Samples for proteomics/epi[INVESTIGATOR_7009]/biobanking (fasting samples preferred ) 
□ Ensure  the subject has had an opportunity to eat a meal prior to cognitive and motor  testing  
□ Perform cognitive and motor testing in the following order  unless otherwise specified : 
1. Savonix Full Battery  
2. ADAS -Cog/[ADDRESS_1020772] -SOB (subject and trial partner) 
6. ADCS -ADL 23 (trial partner) 
7. ADCS -CGIC (subject  and trial partner )  
8. NPI-Q (trial partner self-administered ; may be completed by [CONTACT_746284])  
 
Visit 10  (Day 56 ±7 days) and Visit 18 (Day 140 ±7 days) 
□ Review AEs and concomitant medication  
□ Collect the following:  
o Vital signs   
o Blood and urine samples for comprehensive laboratory panel (fasting samples preferred)  
o Samples for proteomics/epi[INVESTIGATOR_7009]/biobanking ( fasting samples preferred ) 
□ Ensure  the subject has had an opportunity to eat a meal prior to cognitive and motor  testing  
□ Perform cognitive assessments in the following order  unless otherwise specified :  
1. Savonix Full Batter y  
2. ADCS -ADL 23 (trial partner) 
3. NPI-Q (trial partner self -administered ; may be completed by [CONTACT_746284])  
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 39 of 100  
7.3.6 FINAL STUDY VISIT  
 
Visit 19, End of Study  (Day 168 ±7 days) 
□ Review AEs and concomitant medication  
□ Collect the following:  
o Vital signs  and subject’s weight in kilograms 
o Blood and urine samples for exit laboratory panel (fasting samples preferred)  
o Samples for proteomics/epi[INVESTIGATOR_7009]/biobanking ( fasting samples preferred ) 
□ Perform the physical exam  
□ Ensure  the subject has had an opportunity to eat a meal prior to cognitive and motor  testing  
□ Perform cognitive and motor testing in the following order  unless otherwise specified : 
1. MMSE  
2. Savonix Full Battery  
3. ADAS -Cog /[ADDRESS_1020773] -SOB (subject and trial partner) 
7. ADCS -ADL 23 (trial partner) 
8. ADCS -CGIC (subject  and trial partner )  
9. NPI-Q (trial partner self -administered; may be completed by [CONTACT_746284])  
□ Complete MRI  
 
Note: Visit [ADDRESS_1020774] withdraws from the study 
early but is willing to provide the second (final) CSF sample  (and has consent ed and is eligible  to participate in the 
optional CSF biomarker research), th is can be obtained as long as the subject received at least two  infusions of 
GRF6019.  
 
7.3.8 SCHEDULE OF EVENTS TABLE 
 
A tabular summary of all procedures that will be accomplished at each study visit  can be found in Section 17 
Schedule of Events . 
 
7.4 CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES  
 
All prescription, over -the-counter, and non-prescription medications (including herbal therapi[INVESTIGATOR_746244] ) must 
be documented in the source documents and CRFs .  All subjects should be maintained on the same medications at the 
same dosage and administration  for treatment of AD throughout the entire study period, as medically feasible, with no 
introduction of new chronic therapi[INVESTIGATOR_014] .  Any changes in medications should be documented with reason for change (e.g., 
adverse event, etc.).  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 40 of 100  
7.5 PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDURES  
 
The following are prohibited:  
• Concurrent participation in another therapeutic treatment trial for AD.  If there was prior clinical trial 
participation, then the last dose of the investigational agent for symptomatic therapi[INVESTIGATOR_746245] 30 
days (or 5 half -lives whichever is longer), 4 months for disease modifying therapi[INVESTIGATOR_014], and 1 year for vaccine or 
immunotherapy trials prior to screening. 
• Concurrent daily treatment with benzodiazepi[INVESTIGATOR_1651], long-acting opi[INVESTIGATOR_2438], or other  medications that, in the 
investigator’s opi[INVESTIGATOR_1649], interfere with cognition.  [Note: intermittent treatment with low -doses of shorter half -life 
benzodiazepi[INVESTIGATOR_1651] (e.g. lorazepam, alprazolam) may be permitted, provided that no dose is administered within the 
72 hours preceding any cognitive assessment].   
• Any anticoagulant therapy; antiplatelet drugs (e.g., aspi[INVESTIGATOR_87494]) are acceptable . 
• Any drugs of the interferon class . 
• Systemic steroids (e.g., hydrocortisone, cortisone, betamethasone, prednisone, prednisolone, triamcinolone, 
dexamethasone, fludrocortisone)  for longer than 5 consecutive days ; ophthalmic, topi[INVESTIGATOR_2855], intra -articular and 
inhaled steroids are allowed.  
 
[ADDRESS_1020775] is essential .  Any instances of unblinding will be managed as indicated 
in Section 10.6.3 Breaking the Study Blind/Par ticipant Code . 
 
8.1 SPECIFICATION OF SAFETY PARAMETERS  
 
8.1.1  DEFINITION OF ADVERSE EVENTS (AE)  
 
Per 21 CFR 312.32(a) an AE is any untoward (unfavorable, harmful, or pathologic) medical occurrence in a subject 
administered a medicinal (investigational) product even if the event does not necessarily have a causal relationship 
with this treatment.    
An AE can therefore be an y unfavorable and unintended sign (including an abnormal laboratory finding that is 
deemed clinically significant), symptom, or disease temporally associated with the use of a medicinal  
(investigational) product whether or not related to the medicinal  (invest igational) product .   
 An AE does include any:  
• Exacerbation of a pre -existing illness  
• Subjective or objective symptoms spontaneously offered by [CONTACT_3184]/or observed by [CONTACT_746285]  
• Increase in frequency or intensity of a pre-existing epi[INVESTIGATOR_746246]# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 41 of 100  
• Condition detected or diagnosed after study drug administration even though it may have been present prior to 
the start of the study  (unless it can be demonstrated by [CONTACT_746286]/time of Informed Consent)  
• Continuous persistent disease or symptoms present at baseline that worsen following the start of the study  
• Symptoms associated with disease not previously reported by [CONTACT_423] 
• Lack of efficacy in the acute treatment of a life-threatening disease  
• Untoward medical occurrences considered by [CONTACT_110190]-mandated procedures  
• Abnormal assessments (e.g., change on physical examination, ECG findings), if they represent a clinically 
significant finding, that were not present at Baseline or worsened during the course of the study  
• Laboratory test abnormalities, if they represent a clinically significant finding, symptomatic or not, which were 
not present at Baseline or worsened during the course of the study  
 
An AE DOES NOT  include a/an:  
• Elective m edical or surgical procedure (e.g., surgery, endoscopy, tooth extraction, transfusion)  
• Pre-existing diseases or conditions present or detected at the start of the study that do not worsen  
• Situa tions where an untoward medical occurrence has not occurred (e.g., hospi[INVESTIGATOR_339374], social and/or convenience admissions)  
• The disease or disorder being studied or sign or symptom associated with the disease or disorder unless more 
severe than expected for the subject’s condition  
• Overdose of either study drug or concurrent medication without any signs or symptoms.  
• Symptoms associated with AD that are consistent with the subject’s usual clinical course unless the symptom(s) 
meet( s) the criteria for “serious” 
• Pregnancy  
 
8.1.2  DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
 
An SAE is any AE occurring at any dose that results in any of the following outcomes (note that if either the 
investigator or the Sponsor believes that the event is serious, the event must be considered serious and evaluated for 
expedited reporting) .  Note that the terms “severe” and “serious” are not synonymous.  Severity (or intensity) refers 
to the grade of an AE .  “Serious” is a regulatory definition .  A serious adverse event (experience) or reaction is an 
untoward medical occurrence that, at any dose , fulfills one or more of the following criteria:  
a. Results in death (i.e., the AE actually causes or leads to death)  
b. Is life-threatening  
• An AE  is considered “life-threatening” if, in the view of either the investigator or Sponsor, its occurrence 
places the patient or subject at immediate risk of death; it does not include AEs which , had it occurred in a 
more severe form, might have caused death  
c. Results in inpatient hospi[INVESTIGATOR_1081].  
• Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen during the study is not considered an AE  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 42 of 100  
• Complications that occur during hospi[INVESTIGATOR_42244] s; if a complication prolongs hospi[INVESTIGATOR_059], the 
event is an SAE  
• “Inpatient” hospi[INVESTIGATOR_124493] a hospi[INVESTIGATOR_746247]; it does not include presentation at a casualty or emergency room  unless 
the event meets the definition of an Important Medical Event (in the opi[INVESTIGATOR_12182])  
d. Results in p ersistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions  
• The term ‘disability’ means a substantial disruption of a person’s ability to conduct normal life functions; this definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, accidental trauma (i.e., sprained ankle) that may interfere or prevent everyday life functions but do not constitute a substantial disruption  
e. Results in a congenital anomaly in the offspring of a subject who received drug  
f. Results in an Important Medical Event .  Important Medical Events are events that may not result in death, be life -
threatening, or require hospi[INVESTIGATOR_124495], based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition; examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias  or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse  
• Medical and scientific judgment should be used in deciding whether prompt reporting is appropriate in this situation  
 
8.[ADDRESS_1020776] be assessed for its seriousness and severity .  Severity will be 
assessed by [CONTACT_746287]:  
 
SEVERITY  DEFINITION  
MILD  Aware of sign or symptom, but easily tolerated  
MODERATE  Discomfort enough to cause interference with usual 
activity  
SEVERE  Incapacitating with inability to work or do usual activity  
 
Outcome will be assessed using the following categories: recovered/resolved, not recovered/ not resolved, 
recovered/resolved with sequelae, fatal, or unknown.  
 
8.2.2  RELATIONSHIP TO STUDY AGENT  
 
Investigators are required to assess the causal relationship (i.e., whether there is reasonable possibility that the study drug caused the event) using the following definitions:  
• Unrelated : another cause of the adverse event is more plausible; a temporal sequence cannot be established 
with the onset of the adverse event and administration of the study agent; or a causal relationship is 
considered biologically implausible.  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 43 of 100  
• Possibly Related: There is a clinically plausible time sequence between onset of the adverse event and 
administration of the study agent, but the adverse event could also be attributed to concurrent or underlying 
disease, or the use of other drugs or procedures .  Possibl y related should be used when the study agent is one 
or several biologically plausible adverse event causes.  
• Definitely Related : The adverse event is clearly related to use of the study agent.  
 
If either the investigator or the Sponsor considers the event related, then the event will be considered related for 
reporting purposes.   
 
8.2.3  EXPECTEDNESS 
 
The Sponsor or designee will be  responsible for determining whether an AE is expected or unexpected .  An AE will 
be considered unexpected if the nature, severity, or frequency of the event is not consistent with the Reference Safety 
Information described in the Investigator’s Brochure .   
 For example, under this definition, hepatic necrosis would be unexpe cted (by [CONTACT_14213]) if the 
investigator brochure referred only to elevated hepatic enzymes or hepatitis.  Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by [CONTACT_14214]) if the Investigator’s Brochure listed 
only cerebral vascular accidents.  "Unexpected" as used in this definition, also refers to AEs or suspected adverse 
reactions that are mentioned in the Investigator’s Brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug but are not specifically mentioned as occurring with the particular drug 
under investigation.  For example, although angioedema is anticipated to occur in some patients exposed to drugs in the angiotensin-converting enzyme (ACE) inhibitor class and angioedema would be described in the Investigator’s 
Brochure as a class effect, the first case of angioedema observed with the drug under investigation should be considered unexpected for reporting purposes ( FDA 2012
). 
 This definition of “unexpected” relies entirely on the Reference Safety Information in the Investigator’s Brochure as the basis for determining if newly acquired information generated from clinical trials or reported from other sources is unexpected.  The suspected adverse reactions listed in the Investigator’s Brochure (i.e., “expected”) are those 
observed with the investigational drug and for which a causal relationship between the event and the drug is 
suspected or confirmed.  
 Sponsor assessment of expectedness and relationship to study drug/causality will determine the need for expedited reporting of AEs.  
 
8.[ADDRESS_1020777] has had an opportunity to 
spontaneously mention any problems, the investigator should inquire about AEs by [CONTACT_7939] a non-leading question such 
as the following:  
1. “How are you feeling?” 
2. “Have you had any changes since your last assessment/visit?” 
3. “Have you taken any new medicines since your last assessment/visit?”  
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020778] 
completes the study  (or has their last visit ) that the investigator judges may be reasonably related to study treatment 
or study participation.  
 
8.[ADDRESS_1020779] be described as follows: the date of onset, date of resolution, severity (mild, moderate, severe), frequency of the event (single epi[INVESTIGATOR_1865], intermittent, continuous), action taken with study 
treatment (no action taken, treatment held, treatment discontinued), outcome, causality* (unrelated, possibly related, definitely related), and seriousness criteria.  Each AE or suspected adverse reaction must be recorded separately.  
 *Note: Causality assessment will be made only when the AE occurs after the subject has initiated at least one 
infusion of the study agent.  An AE occurring before the subject’s exposure to study agent will always be labeled as  
“unrelated”.  
 Any AE occurring during the study must be documented in the subject’s medical records and as an AE in the CRF.  
Any SAE occurring during the study must be documented in the subject’s medical records and as an SAE in the 
CRF.  A separate set of SAE pages should be used for each SAE.  However, if at the time of initial reporting, multiple 
SAEs are present that are temporally and/or clinically related, they may be reported on the same SAE page.  
 The investigator should attempt to establish a diagnosis of the event (that meets the definition of an AE or SAE) based on signs, symptoms, and/or other clinical information.  In such cases, the diagnosis should be documented as the AE and/or SAE and not the individual signs or symptoms.  The diagnosis wi ll become the basis for the verbatim 
term as reported by [CONTACT_093].  If no diagnosis is known and clinical signs and symptoms are not present, the abnormal finding should be recorded.  
 In addition to the investigator’s own description of the AE, eac h AE will be encoded according to the MedDRA.  
 The investigator will take all appropriate and necessary therapeutic measures required for resolution of the AE.  Any medication necessary for the treatment of an AE must be recorded on the concomitant medicat ion CRF.   
 The SAE pages of the CRF should be completed as thoroughly as possible and signed by [CONTACT_15009]/her designee before transmittal to the study Contract Research Organization (CRO).  It is very important that the investigator provide his/her assessment of causality to study drug as well as an applicable diagnosis at the time of the 
initial SAE report.  
 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 45 of 100  
8.4.2  SERIOUS ADVERSE EVENT REPORTING  
 
[IP_ADDRESS]  Timeframes for Reporting SAEs 
Under 21 CFR 312.32(c), the Sponsor is required to notify FDA and all participating investigators in a safety report 
of potentially serious risks from clinical trials [i.e., Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]RS)], as 
soon as possible after the Sponsor receives the safety information and d etermines that the information qualifies for 
reporting:  
 
• No later than 7 calendar days for events that are life threatening (in the opi[INVESTIGATOR_746248]) or that involve Death as an outcome.  
• No later than 15 calendar days for all other S[LOCATION_003]RS.  
 
As such, prompt notification of the Sponsor, and/or the Sponsor’s representatives, and promptly providing requested 
follow -up information regarding SAEs is essential so that ethical and regulatory responsibilities and legal obligations 
can be satisfied.  Investigators are responsible for reporting SAEs according to the following timeframes:  
 
• All SAEs occurring during the study should be reported immediately.  
• The SAE Report Form and relevant source documents, if applicable, must be completed and emailed to 
[EMAIL_2477]  within 24 hours of observation or learning of the event.  
• Follow -up information must be sent to the CRO within [ADDRESS_1020780] to follow up.  
 
[IP_ADDRESS]  SAE Information to Report  
All information available regarding an SAE must be submitted in the timeframes indicated.  At a minimum, SAE 
reports must contain the subject ID, the SAE verbatim term, onset date, relationship to study drug/causality, and a brief narrative of the event.  Please note that relationship to study drug/causality as well as the reported verbatim 
term are very important  and should be included in the initial report as it may impact expedited regulatory reporting 
requirements for the event.  T he date of SAE discovery by [CONTACT_422386].  
 The investigator must record all relevant information regarding an AE/SAE in the applicable sections of the CRF.  It 
is not acceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical records in lieu of completion of the 
appropriate AE/SAE pages.  However, there may be instances when copi[INVESTIGATOR_258537]/or the Sponsor.  If medical records are submitted to the CRO then all subject personal identifiers must be completely and thoroughly redacted prior to submission.  
 
A blank SAE Report Form and instructions for SAE reporting will be provided to the site and will be maintained in the investigator’s study file .  The SAE Report Form must be completed and emailed to [EMAIL_2477]
 
according to the timeframes specified in Section 8.4. 2.1.  The SAE Report Form should include copi[INVESTIGATOR_746249], if applicable.  Reconciliation of any discrepancy noted during monitoring and amending the CRF 
is required.  
 
If new information about an SAE is received or corrections to data are needed, the investigator should complete a 
new SAE Report Form and check the “follow -up” box on the form.  This follow -up SAE Report Form should be 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 46 of 100  
submitted within 24 hours of learning of the information, especially if the new information concerns seriousness, 
relatedness, or the event term of an AE.  
 Sites acting under their local IRB should submit all applicable events, unanticipated problems, and safety reports to the site’s local IRB, if applicable.  All safety reporting deviations should also  be submitted to their local IRB, if 
applicable.  
   
8.4.[ADDRESS_1020781] (AESI):  
• Clinically-significant peripheral edema or pulmonary edema.  
• Systolic blood pressure (BP) <  90 or >  160 mm Hg and/or diastolic BP <  60 or >  100 mm Hg, or a change 
of > 25% from Day 1 (Visit 3) pre-infusion systolic and/or diastolic BP.   
• Reduced kidney function (eGFR < 45 mL/min/1.73 m2).  
• Suspected transmission of blood- borne infectious agents.  
 
AESI occurring during the study should be reported within [ADDRESS_1020782] be reported according to the timeframes specified in Section 
[IP_ADDRESS] . 
 
8.4.[ADDRESS_1020783]’s  last dose.  All pregnancies will be reported to the IRB, Sponsor, and 
CRO.  In the event of a pregnancy, treatment will be discontinued, and the subject will undergo continued safety follow -up through pregnancy outcome.  
 
Any pregnancy must be followed by [CONTACT_179130].  Any anomalies, 
complications, abnormal outcomes, or birth defect observed in the child must be reported as an SAE within 24 
hours of the investigator or study personnel’s first knowledge.  
 
8.5 STUDY HALTING RULES  
 
If any of the following safety events occur, a Safety Evaluation Meeting  (defined below) will be triggered : 
• Three or more SAEs in the same system/organ/class (SOC) that are assessed as possibly or definitely related to 
the study agent by [CONTACT_167073] (see Section 8.2.2 Relationship to 
Study Agent ). 
• Within or between any of the  dosing groups : an overall pattern of symptomatic, clinical, or laboratory events 
associated with the study agent that the Sponsor’s Program Physician  or designee consider  a serious potential 
safety concern  (e.g. suspi[INVESTIGATOR_179095]) . 
Events that are more likely related to the infu sion procedure, such as infiltration or hematoma, will not be considered 
“drug re lated” and will not contribute to the  count of definitely-re lated SAEs that would trigger a Safety Evaluation 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 47 of 100  
Meeting . 
 
Safety Evaluation Meeting 
If safety events of potential concern occur during the trial (as defined above)  a Safety Evaluation Meeting will be 
triggered , and dosing may be temporarily halted based on the observations .  The Sponsor will inform investigators and 
the FDA in the event of any temporary halt in dosing  at any time during the conduct of the study.  The purpose of the 
meeting  is for investigators, the Sponsor , and the CRO Medical Monitor to discuss and evaluate the safety of the subjects 
using available aggregated safety data a nd without compromising study blinding .   
 
Attendants at the Safety Evaluation Meeting will include the Alkahest  Program Physician (or his/her designee), the CRO 
Medical Monitor , and a majority of  active investigators participating in the trial.  After sufficient data review the Sponsor 
will choose one of the following courses of action: 
1. Continue dosing with no change to protocol . 
2. Halt dosing in all group s and stop the study.  
3. Continue  with a modified protocol design and amend the protocol as appropriate . 
 
8.6 SAFETY OVERSIGHT  
 
Safety oversight will be provided by [CONTACT_10577] ’s Program Physician  or his or her designee  and the CRO’s Medical 
Monitor  in concert with the Principal Investigators  at each participating site.  As all subjects are on active drug , there will 
be no formal Data Safety Monitoring Board (DSMB)  established .  As needed,  blinded Safety Evaluation  Meetings will 
be convened as descri bed in Section 8.5  to monitor the ongoing safety of the study.  The Sponsor’s Program Physician  or 
designee is the final authority for safety oversight  in the study. 
 
[ADDRESS_1020784] of the trial is in compliance with the currently approved protocol/a mendment(s), with GCP, and with applicable regulatory requirement(s).  
 
• Monitoring for this study will be performed by [CONTACT_746288] 
(CMP). 
• A mix of on- site and centralized risk -based monitoring will be performed to ensure the safety of clinical 
subjects and the accuracy and completeness of study data.   
• The Sponsor  will be provided with copi[INVESTIGATOR_746250] . 
• Details of clinical site monitoring are documented in the Study’s  CMP .  The CMP describes in detail who 
will conduct monitoring, at what frequency monitoring will be done, at what level of detail monitoring will 
be performed, and the distribution of monitoring reports.  
• Independent audits may be conducted by [CONTACT_746289]’s  clinical quality 
oversight plan or equivalent to ensure monitoring practices are performed consistently across all participating 
sites and that monitors are following the CMP.  
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 48 of 100  
10 STATISTICAL CONSIDERATIONS 
10.1 STATISTICAL AND ANALYTICAL PLANS  
A Statistical Analysis Plan (SAP) with analytical details and assumptions will be developed during the conduct of the 
study.  The finalization of the SAP will occur prior to clinical database lock  and unblinding of the study data . 
 
10.[ADDRESS_1020785] amounts of hypothesis testing; within-subject changes from 
baseline for each dosing group  and among- group  differences will be evaluated .   
 
10.3 ANALYSIS DATASETS  
 
Four analysis datasets are possible however, analyses may not necessarily be conducted with all four: 
 
• Intention-to-Treat (ITT) Dataset : all randomized  participants . 
• Safety Dataset : all subjects who received at least one dose of the study agent.   
• Evaluable Dataset:   all subjects who receive at least 5 of the 10 planned doses.  
• Per Protocol Dataset:   a subset of the Evaluable Dataset comprised of subjects who have no 
Major Protocol Deviation s. 
 
The presentation  of baseline characteristics will be conducted on the ITT dataset .  All safety analyses will be performed 
for the Safety Dataset .  Analyses of the secondary endpoints will focus on the  Evaluable and/or Per Protocol D atasets. 
 
10.4 DESCRIPTION OF STATISTICAL METHODS  
 
10.4.1  GENERAL APPROACH  
 
Using the Evaluable and/or Per Protocol  Dataset s, all secondary cognitive -score endpoints (e.g., MMSE, 
ADAS -Cog, etc.) will be summarized serially over time using  descriptive statistics  to assess the within -
subject chang es and among -group differences .  Overall baseline and demographic data will be summarized 
using descriptive statistics; among-groups testing will be used to evaluate the effectiveness of the 
randomization in producing homogeneous pre -treatment group s.   
 
For analysis of the primary and secondary endpoints , the following will be considered:  
• For endpoints that are continuous in nature:  
o Number of observations, mean, median, minimum and maximum, and standard deviation (SD) values will 
be presented as descriptive summary . 
o For inferential statistics:  
 If the Normality assumption is met, Paired t -test, or Analysis of Covariance ( ANCOVA ) using the 
baseline value as a covariate will be used . 
 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 49 of 100  
 If the Normality assumption is not met, a rank –ANCOVA analysis i.e., an ANCOVA analysis on 
rank-transformed data or other non-parametric methods will be used . 
• For endpoints that are categorical in nature:  
o Frequency counts and percentages will be presented as descriptive summary . 
o Chi-square test or Logit model will be used for inferential statistics . 
 
Subject disposition (e.g., the number of subjects randomized , completed, and discont inued) will be 
summarized and medical history data will be listed .  Prior and concomitant medications taken from screening 
and during the study will be categorized by [CONTACT_78464] (WHO) classification for therapeutic class and drug name, listed and summarized by [CONTACT_11840] .   
 Final analyses are not limited to the summaries described herein .  As noted above, analytical details and 
assumpti ons will be fully presented in the SAP. 
 
10.4.2  ANALYSIS OF THE PRIMARY ENDPOINT(S)  
 
Summary tabula tions of the reported adverse events will be presented by [CONTACT_746290] S OCs using the MedDRA Version 21.[ADDRESS_1020786] attribution to the study agent . 
 The AE  analyses will focus on those that are Treatment-E mergent, however any AEs that are reported after 
consent has been  signed and prior to initial dosing will be tabulated as Intercurrent Events.  
 
Additional details are presented in Section 10.4.4
.   
 
10.4.3  ANALYSIS OF THE SECONDARY ENPOINT(S)  
 
The study is not designed to detect significant changes in cognition over time .  However, using available data from 
analysis of the secondary endpoints, including changes in cognition scores from baseline, descriptive 
summarization will be developed .  Of particular interest will be the within -subject changes from baseline and their 
distribution around a null value of zero and a comparison among groups to evaluate any trends in dose response.  
Appropriate paired sample tests (paired t -test or Wilcoxon Signed Rank tests) may be conducted to evaluate 
within -subject changes from baseline, using a two -tailed α-level of 0.[ADDRESS_1020787].  Alternatively, since the dose groups are 
ordinal, regression and graphical methods may be employed to evaluate any dose -response trends.  
 
10.4.4  SAFETY ANALYSES  
 
Safety, tolerability, and feasibility will be evaluated by [CONTACT_84775], including Treatment-
Emergent AEs, and AEs leading to discontinuation from the study.  AEs will be summarized by [CONTACT_746291] .   
 Actual and changes from baseline in clinical laboratory measure ments and vital signs will also be assessed and 
summarized .  Abnormal values will be determined and flagged in the listings .  Laboratory shift tables or graphics 
displaying the change (number of subjects) relative to the reference range from baseline to each study visit may 
also be presented for each test .  The investigator should exercise his or her medical and scientific judgment in 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020788] s, as appropriate.  
 
10.4.6  BASELINE DESCRIPTIVE STATISTICS 
 
See Section 10.4.1 . 
 
10.4.7  PLANNED INTERIM ANALYSES  
 
No interim analyses are planned .  If a S afety Evaluation Meeting  is triggered (see Section 8.5 ), an ad  hoc interim 
safety analysis will be performed .  If such an ad hoc safety interim analysis is conducted, the dose assignment will 
remain masked .   
 
10.4.8  ADDITIONAL SUB -GROUP ANALYSES  
 
Not applicable.  
 
10.4.9  MULTIPLE COMPARISON/MULTIPLICITY  
 
No adjustments for multiplicity will be employed.  
 
10.4.10  TABULATION OF INDIVIDUAL RESPONSE DATA 
 
This will be further defined in the SAP . 
 
10.4.11  EXPLORATORY ANALYSES  
 
Not applicable.  
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 51 of 100  
10.5 SAMPLE SIZE  
 
A total of 4 0 subjects (20 in the 100 mL group  and 20 in the 250 mL group) will be random ized in the study with the 
intent of obtaining ~ [ADDRESS_1020789] 5 doses and completed through Visit 8 .  Subjects 
who discontinue prior to completing Visit 8 may be replaced .  Subjects who withdraw or are withdrawn during screening 
will be replaced .  Subjects who are randomized but do not receive any dose of the study agent , may be re-screened and 
randomized if they meet all of the study eligibility requirements.  
 
The study is not powered for detecting statistically significant differences in pharmacodynamic parameters or to assess the cognitive effects of GRF6019  infusions in AD .  However, using the statistical approximation described by [CONTACT_179133] 
(aka the “Rule of Threes”), the upper bound of the 95% confidence interval for the rate of an unreported AE is at most 
5.0% (3/number of subjects receiving active drug) .  In addition, the proposed sample size may be sufficient to identify 
trends in the effects of plasma-derived factors and in the relationship between dose and response . 
 
10.6 MEASURE TO MINIMIZE BIAS  
 
10.6.1  ENROLLMENT/RANDOMIZATION/MASKING PROCEDURES 
 
To minimize the potential bias, the study will be double -blinded at randomization and through the end of study.  A 
stratified permuted block randomization will be implemented by [CONTACT_4321].  The randomization will be web -based and 
centralized.  The randomization codes will be ge nerated by a statistician who has no involvement in the study other 
than generation and maintenance of the randomization codes.   
 All study outcome measures will be assessed by [CONTACT_746292].  However, study agent  and 
information regarding the volume  to be administered , will be provided by [CONTACT_21703] , or other 
qualified staff responsible for drug accountability,  to an unblinded Infusion Nurse.  Administration of the study 
agent will be performed by [CONTACT_179114].  To ensure that Outcomes Assessors, subjects, and trial 
partners are unaware of the dose being administered, appropriate measures will be taken to mask the infusion pump 
and glass vial (s) containing the study agent such that they  will only be visible  as necessary  to the unblinded Infusion 
Nurse for appropriate dosing.  In addition, a curtain , drape , or equivalent will be used to shield the infusion 
administration setup from view  of all but the unblinded Infusion Nurse, and the unblinded Infusion Nurse will be 
responsible for concealing and returning used and partially used vials to the pharmacy at the end of the Infusion 
Period .   
 Communication between the Outcomes Assessor and the Infusion Nurse will be restricted to only th at required to 
ensure immediate safety of subjects (e.g. requests to start/stop/change infusion rates outside of the standard infus ion 
protocol due to AEs) .  The Outcomes Assessors will observe th e subject during the infusion of the study agent  and 
collect and/or manage/report AEs and SAEs.   
 
 
 
  
 Except for the unblinded CRA(s) whose sole responsibility is to ensure the study agent is being dispensed, administered , and disposed of  properly, the study Sponsor and their representatives will be blinded with respect to 
dose.  

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 52 of 100  
 
10.6.2  EVALUATION OF SUCCESS OF BLINDING  
 
Evaluation of success of blinding will be assessed as part of study feasibility.  Success of blinding will be assessed 
based on all occurrences (intentional or unintentional) of unblinding of blinded study subjects, their trial partners , or 
study personnel  (e.g. investigators, medical providers, cognitive testing raters, the Sponsor , or their representatives) .  
All intentional and unintentional unblinding will be documented and reported.   
 
10.6.3  BREAKING THE STUDY BLIND/PARTICIPANT CODE  
 
Due to the dose-comparison concurrent control study design, it is not expected that the study blind would need to be 
broken for safety reasons .  Any noted intentional or  unintentional breaking of the blind should be reported to the 
Sponsor’s Study Team Lead.  Subjects who  have been unblinded prior to dosing day 5 will be replaced .  If 
unintentional unblinding occurs during the study, root cause analysis will be evaluated, and corrective actions implemented.  
 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  
 
Each par ticipating site will maintain appropriate medical and research records for this trial, in  compliance with  
ICH E6  R2 and regulatory and institutional requirements for the protection of confidentiality of participants .  Each site 
will permit authorized representatives of regulatory agencies, the IRB/IEC , the Sponsor , or the Sponsor’s representati ves 
to examine (and when permitted by [CONTACT_1289], to copy) clinical records for the purposes of quality assurance 
reviews, audits, and evaluation of the study safety, progress, and data validity .   
 
Source data are all information,  original records  of clinical  findings,  observations,  or other activities in a clinical trial 
necessary for the reconstruction  and evaluation of the trial.  Examples  of these  original documents and data records  
include, but are not limited  to, hospi[INVESTIGATOR_20112], clinical  and office charts, laboratory notes, memoran da, participant’s 
memory aids or evaluation checklists, pharmacy dispensing records, recorded audio tapes of counseling sessions, 
recorded data from automated instruments, copi[INVESTIGATOR_746251],  microfiches,  photographic negatives,  microfilm  or magnetic  media,  x-rays,  and participant  files and records  
kept at the pharmacy, at  the laboratories, and medico -technical  departments  involved in the clinical  trial.   
 
It is not acceptable for the CRF to be the only record of a subject ’s participation in the study.  This is to ensure that 
anyone who would access the subject’s  medical record has adequate knowledge that the subjec t is participating in a 
clinical trial.  So urce document templates  will be developed for this study.  
 
12 ETHICS/PROTECTION OF HUMAN SUBJECTS  
12.[ADDRESS_1020790]  
 
The investigator will ensure that this study is conducted in full conformity with Regulations for the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, ICH E6  R2, 21 CFR, part 320, 1993, 
Retention of Bioavailability and Bioequivalence Testing Samples and the Declaration of Helsinki.  
 
 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020791] (such as advertisements, subject information 
sheets, or descriptions of the study used to obtain informed consent) will be submitted by [CONTACT_624485].  Approval f rom the IRB/ IEC must be obtained before starting the study and should be documented in a letter to the 
investigator specifying the protocol number, protocol version, documents reviewed, and date on which the committee met and granted the approval .   
 All c hanges to the consent form will be IRB approved; a determination will be made regarding whether previously 
consented participants need to be re-consented.  Any modifications or amendment to the protocol must also be submitted to the IRB/ IEC for approval pr ior to 
implementation.  
 
12.3 INFORMED CONSENT PROCESS  
 
12.3.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS 
 
Consent forms describing in detail the study agent, study procedures, and risks are given to the subject  (or the 
subject’s legally authorized representative) and trial partner .  Written documentation of informed consent is required 
prior to any invasive st udy procedures .  The following consent materials are submitted with this protocol : 
• ALK6019-[ADDRESS_1020792] 
participating in this study and/or their legally authorized representative and the subject’s trial partner (if not the same 
person as the legally authorized representative) after adequate explanation of the aims, methods, objectives, and potential hazards of the study and prior to undertaking any study-related procedures.  
 Subjects and/or trial partners should have the opportunity to discuss the study with their family members or other 
advisors and the time to consider participation in the trial carefully.  P articipants may withdraw consent at any time 
throughout the course of the trial .  The rights and welfare of the participants will be protected by [CONTACT_746293].  
 The investigator or designee must utilize an IRB /IEC -approved consent form that contains the elements required by 
[CONTACT_124543] .  Each informed consent 
will be appropriately signed and dated by [CONTACT_3184]/or their legally authorized representative and the subject’s  
trial partner (if not the same person as the legally authorized representative) and the person obtai ning consent .  A 
copy of the signed consent form will be provided to the subject and/or their legally authorized representative and the 
trial partner (if not the same person as the legally authorized representative) .  By [CONTACT_1725], 
all parties agree they will complete the evaluations required by [CONTACT_1758], unless they withdraw voluntarily or are 
terminated from the study for any reason.  
 Investigators will be expected to maintain a screening log of all potential study candidates that includes limited 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 54 of 100  
information about the potential candidate (e.g., date of screening) .   
 
All subjects who provide consent will be assigned a unique study number .  This number will be used to identify the 
subject throughout the clinical study and must be used on all study documentation related to the study subject .  Once 
a number is assigned to a subject, that number will remain with that study subject and will not be reused.  
 
If an individual’s medical chart or results of diagnostic tests performed as part of an individual’s regular medical  care are going to be used  for screening,  written  informed consent  must  be obtained  prior to review  of 
that information in accordance with 
HIPAA.  
 
The Screening period for a subject commences at the point at which the subject signs the informed consent form and 
must be completed within [ADDRESS_1020793] party without prior written approval of the Sponsor.  
 
The study monitor, other authorized representatives of the Sponsor, representatives of the IRB/IEC  or government 
regulatory agencies may inspect documents and records required to be maintained by [CONTACT_093], including but not 
limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study .  The 
clinical study site will permit access to such records.  
 
The investigator must assure that subjects’ anonymity will be strictly maintained and that their identities are protected from unauthorized parties .  Only subject initials and an identification code (i.e., not names) should be recorded on non-
local lab samples, requisitions and any documents submitted to the CRO, Sponsor and/or IRB/IEC .  The investigator 
must keep a subject log showing codes, names, and addresses for all subjects screened and for all subjects enrolled in the trial.  The study subject ’s contact [CONTACT_179138].  At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_15686]/IEC and Institutional regulations.  
 
12.[ADDRESS_1020794] ’s (or the subject’s legally authorized representative’s)  approval and as approved by [CONTACT_746294] , de-identified biological samples may be stored by [CONTACT_124546] , or designee,  indefinitely for future use .  
These samples could will be used for research into the causes of AD, its complications , and other conditions for which 
elderly individuals are at increased risk, and to improve treatment options .  Alkahest will also be provided with a code -
link that will allow linking the biologic al specimens with the phenotypic data from each subject , maintaining the masking 
of the identity of the study subject . 
 During the conduct of the study, an individual subject can choose to withdraw consent to have biological specimens 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 55 of 100  
stored for future res earch .  However, withdrawal of consent for biospecimen  storage will not be possible after the study is 
completed . 
 
When the study is completed, access to study data and/or samples will be managed by [CONTACT_124546] .  In the event Alkahest 
transfers ownership to another commercial sponsor, ownership of the samples may be transferred as well.  
 
[ADDRESS_1020795] be compliant  with applicable ICH GCP.  
 
13.1.1 INVESTIGATOR RESPONSIBILITIES 
 
The investigator will comply with the protocol (which has been approved/given favorable opi[INVESTIGATOR_124503]/ IEC), 
ICH GCP, and applicable regulatory requirements as described in the Clinical Study Agreement .  The investigator is 
ultimately responsible for the conduct of all aspects of the study at the study site and verifies by [CONTACT_179140].  The term “investigator” as used in this protocol as well as in other 
study documents, refers to the investigator or authorized study personnel that the investigator has designated to perform certain duties .  Sub -investigators or other authorized study personnel are eligible to sign for the investigator, 
except where the investigator’s signature [CONTACT_1788].  
 
13.1.[ADDRESS_1020796] of the study to be fully documented and the study data to be subsequently verified.  These documents should be classified into two separate 
categories (although not limited to) the following: (1) investigator’s study file, and (2) subject clinical source documents.  
 
The investigator’s study file will contain the protocol/amendme nts, CRF and query forms (if paper CRFs are 
utilized), IRB/IEC approval with correspondence, informed consent, drug records, staff curriculum vitae and 
authorization forms, and other appropriate documents and correspondence.  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020797] clinical source documents would include (although are not limited to) the following: subject hospi[INVESTIGATOR_307]/clinic 
records, physician’s and nurse’s notes, appointment book, original laboratory reports, ECG, radiologic imaging, X -
ray, pathology and special assessment reports, consultant letters, screening and enrollment log, etc.  
 
13.[ADDRESS_1020798] be retained by [CONTACT_746295] I nvestigational New Drug 
(IND) application  is discontinued and regulatory authorities have been notified.  Before the investigator destroys any 
material related to the clinical study, he/she must obtain approval in writing from the Sponsor.  
 
The investigator should keep a file where the full name [CONTACT_746306] [ADDRESS_1020799], the investigator, or the study site staff.  When deviations  occur , corrective actions are 
to be developed by [CONTACT_3483].  
 
These practices are consistent with ICH E6: 
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and  4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.[ADDRESS_1020800] the rights, safety and/or wellbeing of study participants, or the study outcomes or data quality.  Major Protocol 
Deviations may result in data that are not deemed evaluable for the per protocol analysis and/or may require that subjects 
be discontinued fr om the study.  Major Protocol Deviations are Significant Clinical Issues.  
 Minor Protocol Deviations  are departures from the approved protocol relating to the conduct of a study that does not 
affect the rights, safety and/or wellbeing of study participants, or the study outcomes or data quality.  Minor Protocol 
Deviations do not require review by [CONTACT_7195].  Minor Protocol Deviations would not generally preclude 
subject data from the per protocol analysis population.   
 
Note: persistently missed or incomplete study procedures and/or study evaluations will be considered Major Protocol 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 57 of 100  
Deviations.  
 
All deviations will be logged and tracked by [CONTACT_167079].  Periodic review of Protocol Deviations will inform 
assessment of site performance.  
 It is the responsibility of the site to use continuous vigilance to identify and report deviations promptly to the study CRO and/or Sponsor.  All deviations must be addressed in study source documents.  Protocol Deviations must be sent to the  
local IRB per their guidelines.  The site PI/study staff is responsible for knowing and adhering to their IRB requirements.  
 
13.4 PUBLICATION AND DATA SHARING POLICY 
 
In compliance with T he International Committee of Medical Journal Editors (ICMJE) clinical trials registration policy 
and Section [ADDRESS_1020801] of 2007, this study will be registered  by [CONTACT_746296].gov , a public trials registry which is sponsored by [CONTACT_1055].  
 Notwithstanding the Sponsor’s requirements for registration and data sharing in ClinicalTrials.gov, a ny formal 
presentation or publication of data collected as a direct or indirect result of this trial will be considered as a joint publication by [CONTACT_093](s) and the Sponsor .  In the case of multicenter studies, it is mandatory that the first 
publication be made based on the totality of data obtained from all centers, analyzed as stipulated in the protocol, and presented and interpreted as documented in the final Clinical Study Report .  The resulting publication will name 
[CONTACT_179145] .  Where it is not permitted for all inve stigators to be included 
as authors, the publication will name [CONTACT_124557].  
 Individual investigators may publish data arising from their own subjects .  The investigator will provide the Sponsor with 
copi[INVESTIGATOR_124504] (including abstracts and posters) at least 60 days in advance of submission .  This review is 
to permit the Sponsor to review the communication for accuracy (thus avoiding potential discrepancies with submissions to regulatory authorities), to verify that confidential information is not inadvertently divulged (  
), to allow adequate input or supplementary information that may not have been available to the investigator, 
and to allow establishment of co -authorship.  
 Inves tigators participating in multicenter studies must agree not to engage in presentations based on data gathered 
individually or by a subgroup of centers before publication of the first main publication, unless this has been agreed otherwise by [CONTACT_124549] .  However, in the event that no publication of the overall results has 
been submitted after approval of the Clinical Study Report, investigators may publish results of one or more center’s subjects to the same review as outlined above .  The Sponsor will circulate proposed multicenter publications to all 
investigators for review.  
 Data will be reviewed by [CONTACT_106126].  The study Sponsor will have [ADDRESS_1020802], Inc. or its authorized 
representative before the study drug is shipped.  For this study, each investigator and sub-investigator (as designated on 
the FDA Form 1572) will provide a signed Financial Disclosure Form in accordance with 21  CRF 54 .  Each investigator 

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020803]: normative data for English and Spanish-speaking elderly . J Int Neuropsych Soc. 
2000;6(7):760-769.  
 
ALK-2015-R002. Effects of young and old human plasma on cognition in NODscid mice.  
 Alzheimer’s Association. 2018 Alzheimer's Disease Facts and Figures. Alzheimers Dement. 2018;14(3):367 -429.  
Benton AL . Development of a multilingual aphasia battery: progress and problems . J Neurol Sci. 1969;9:39-48.  
 
 
 
 
 
 Burnouf  
T. Modern plasma fractionation. Transfus Med Rev. 2007;21(2):101- 17. 
 Cai K, Miller JL, Stenland CJ, Gilligan KJ, Hartwell RC, Terry JC, et al. Solven t-dependent precipi[INVESTIGATOR_124505]. Biochim Biophys Acta. 2002;1597:28-35.  
 Food and Drug Administration (FDA), U.S. Department of Health and Human Services. Guidance for Industry and 
Investigators: Safety Reporting Requirements for INDs and BA/BE Studies . December, 2012.  
 Ferris SH, Mackell JA, Mohs R, Scheider LS, Galasko D, Whitehouse P, et al . A multicenter evaluation of new treatment 
efficacy instruments for Alzheimer’s disease clinical trials: overview and general results. Alz Dis Assoc Dis. 
1997;11(Suppl 2):S1-S12.  
 Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of 
patients for the clinician. J Psychiatric Res. 1975;12(3):[ADDRESS_1020804] ivities of daily 
living for clinical trials in Alzheimer’s Disease. Alz Dis Assoc Disord. 1997;11 (Suppl 2):S33-39.  
 Gebhard C, Stahli B, Jenni R, Tanner FC . Effect of age on left ventricular ejection fraction assessed by 
[CONTACT_51541]. Eur Heart J. 2012;33:1.  
 Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Brit J 
Psychiat. 1982;140:566- 572. 
 

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 59 of 100  
Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI -Q, a brief clinical 
form of the neuropsychiatric inventory. J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-239.  
 
Lafayette Instrument Company . Grooved Pegboard Test User Instructions (Model [ZIP_CODE]); 2002.  
Mayeux R . Early Alzheimer’s disease. N Engl J Med. 2 010;362:2194-2201.  
 McKhann GM, Knopman, DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to 
Alzheimer's disease: recommendations from the National Institute on Aging -Alzheimer's Association workgroups on 
diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):[ADDRESS_1020805] for Adults (Conventional Units) | NIDDK. National Institute of Diabetes and Digestive and Kidney Diseases 
Available at: https://www.niddk.nih.gov/health -information/communication-programs/nkdep/laboratory-
evaluation/glomerular -filtration-rate-calculators/mdrd -adults -conventional -units. (Accessed: 16th February 2018)  
 
O’Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. Staging dementia using Clinical Dementia 
Rating Scale Sum of Boxes scores: a [LOCATION_007] Alzheimer’s Research Consortium study. Arch Neurol. 2008;65:1091 -1095.  
 
 
 
Polacchini A, Metelli G, Francavilla R, Baj G, Florean M, Mascaretti LG, et al. A method for reproducible measurements 
of serum BDNF: comparison of the performance of six commercial assays. Sci Rep. 2015;5:[ZIP_CODE].  
 Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al . The Columbia -Suicide Severity Rating 
Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am 
Psychiatry. 2011 December;169(12):1266-1277.  
 
 
 
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):[ADDRESS_1020806], Fuld PA, Katzman R, Peck A. 1980. Pathological verification of ischemic score in differentiatio n 
of dementia. Arch Neurology. 1980;7:486-488.  
 Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg, B, et al. Validity and reliability of the Alzheimer’s 
Disease Cooperative Study -Clinical Global Impression of Change. Alzheimers Dis Assoc Disor d. 1997;11 (Suppl 
2):S22 -S52. 
 
Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, et al. The Alzheimer’s Disease Assessment Scale-
Cognitive -Plus (ADAS -Cog-Plus): an expansion of the ADAS -Cog to improve responsiveness in MCI . Brain Imaging 
Behav. 2012;6 (4):1-24.  
 Stenland CJ, Lee DC, Brown P, Petteway SR Jr, Rubenstein R. Partitioning of human and sheep forms of  
the pathogenic prion protein during the purification of therapeutic proteins from human plasma.  
Transfusion. 2002;42:1497 -500.  
 
Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, et al. T he ageing systemic milieu negatively 
regulates neurogenesis and cognitive function. Nature. 2011;477:90 -94. 

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 60 of 100  
 
Villeda SA, Plambeck KE, Middeldorp J, Castellano JM , Mosher KI, Luo J, et al. Young blood reverses age- related 
impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014 Jun;20(6):659-663.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 61 of 100  
16 APPENDICES  
 
The neurocognitive assessments in this section and associated information are provided as EXAMPLES ONLY.  The 
actual neurocognitive assessments, related source documents, and instructions for administration and scoring are included 
in the Rater Reference Manu al.    
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 62 of 100  
Appendix 1.  Mini-Mental State Examination (MMSE) 
 
Instructions for Administration and S coring  
 
Orientation (10 points):  
• Ask for the date.  Then specifically ask for parts omitted (e.g., "Can you also tell me what season it is?") .  One point for 
each correct answer.  
• Ask in turn, ""Can you tell me the name [CONTACT_124558] (town, county, etc.)?" One point for each correct answer.  
 
Registration (3 points):  
• Say the names of three unrelated objects clearly and slowly, allowing approximately one second for each .  After you have 
said all three, ask the patient to repeat them .  The number of objects the patient names correctly upon the first repetition 
determines the score (0 -3).  If the patient does not repeat all three objects the first time, continue saying the names until the 
patient is able to repeat all three items, up to six trials .  Record the number of trials it takes for the patient to learn the words .  
If the patient does not eventually learn all three, recall cannot be meaningfully tested.  
• After completing this task, tell the patient, "Try to remember the words, as I will ask for them in a little while.”  
 
Attention and Calculation (5 points):  
• Ask the patient to begin with [ADDRESS_1020807] by [CONTACT_124551] .  Stop after five subtractions (93, 86, 79, 72, 65) .  Score 
the total number of correct answers.  
• If the patient cannot or will not perform the subtraction task, ask the patient to spell the word "world" backwards .  The 
score is the number of letters in correct order (e.g., dlrow=5, dlorw=3).  
 
Recall (3 points):  
• Ask the patient if he or she can recall the three words you previously asked him or her to remember .  Score the total 
number of correct answers (0 -3). 
 
Language and Praxis (9 points):  
• Naming: Show the pati ent a wrist watch and ask the patient what it is.  Repeat with a pencil .  Score one point for each 
correct naming (0 -2). 
• Repetition: Ask the patient to repeat the sentence after you ("No ifs, ands, or buts.") .  Allow only one trial .  Score 0 or 1.  
• 3-Stage Command: Give the patient a pi[INVESTIGATOR_124506], "Take this paper in your right hand, fold it in half, and 
put it on the floor." Score one point for each part of the command correctly executed.  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 63 of 100  
• Reading: On a blank pi[INVESTIGATOR_746252], "Close your eyes," in letters large enough for the patient to see 
clearly .  Ask the patient to read the sentence and do what it says.  Score one point only if the patient actually closes his or 
her eyes.  This is not a test of memory, so you may pr ompt the patient to "do what it says" after the patient reads the 
sentence.  
• Writing: Give the patient a blank pi[INVESTIGATOR_746253] a sentence for you.  Do not dictate a sentence; 
it should be written spontaneously.  The sentence must contain a subject and a verb and make sense.  Correct grammar and punctuation are not necessary. 
• Copying: Show the patient the pi[INVESTIGATOR_746254] .  
All ten angles must be presen t and two must intersect to score one point .  Ignore tremor and rotation.  
 
Interpretation of the MMSE  
 
Method  Score  Interpretation  
Single Cutoff  <24 Abnormal  
Range  <21 
>25 Increased odds of dementia  
Decreased odds of dementia  
Education  21 
<23 
<24 Abnormal for 8th grade education  
Abnormal for high school education  
Abnormal for college education  
Severity  24-30 
18-23  
0-17 No cognitive impairment  
Mild cognitive impairment 
Severe cognitive impairment  
   Reference:  
Folstein MF, Folstein SE, McHugh PR. "Mini -mental state." A practical method for grading the cognitive state of 
patients for the clinician. J Psychiatric Res. 1975;12(3):189 -198.  
 
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 64 of 100  
Appendix 2.  Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS -COG/11): Assessment 
Categories, Descriptions, and Scoring  
 
1. Immediate word recall  
   In this task, the subject is given [ADDRESS_1020808]’s score is the average number of words not recalled in 3 trials 
(maximum 10).  
2. Naming objects and fingers  
   For this item, the subject is asked to name [CONTACT_941] 12 real objects presented randomly as well as the fingers of his/her 
dominant hand.  The objects presented: flower, bed, whistle, pencil, rattle, mask, scissors, comb, wallet, harmonica, 
stethoscope, and tweezers.  The score varies from [ADDRESS_1020809]’s ability to copy 4 geometric forms: a circle, a superimposed rectangle, a diamond and a 
square.  Score varies from [ADDRESS_1020810] answer (maximum 8).  
7. Word recognition  
   In this task, the subject must read and memorize a list of [ADDRESS_1020811] order is changed .  The score is calculated.  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020812] instructions  
   This item evaluates the individual’ s ability to remember the instructions of the recognition task.  Score varies from [ADDRESS_1020813] choice.  Score varies from 
0 to 5.  
11. Comprehension  
   This item evaluates the individual’s ability t o understand the examiner’s speech .  Score varies from 0 to 5.  
  
References:  
Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of 
dementia. Arch Neurology. 1980;7:486- 488. 
Skinner J, Carvalho JO,  Potter GG, Thames A, Zelinski E, Crane PK, et al. The Alzheimer’s Disease Assessment Scale-
Cognitive -Plus (ADAS -Cog-Plus): an expansion of the ADAS -Cog to improve responsiveness in MCI. Brain Imag 
Behav. 2012;6:489- 501. 
 
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 66 of 100  
Appendix 3. Clinical Dementia Rating Scale – Sum of Boxes (CDR-SOB) 
The CDR rates the severity of AD using a [ADDRESS_1020814] the 
patient’s ability to function in the 6 cognitive categories of memory, orientation, judgment and problem solving, 
community affairs/involvement, home life and hobbies and personal care .  The CDR is completed by a specially trained 
researcher or clinician after performing a face-to -face, semi- structured interview with the patient and a reliable informant 
(e.g., trial partner).  The informant is interviewed first, and the results of that interview are used to assess patient recall of 
events and to confirm the accuracy of patient responses.  In each cognitive category, the patient receives a score o f 0 (no 
cognitive impairment) to 3 (severe cognitive impairment) .  The CDR can be scored to obtain a global score by [CONTACT_746297], or it can be scored using the sum of boxes (SOB) 
method in w hich all categories are weighted equally; in general, the higher the score, the greater the severity of dementia 
The memory, orientation, judgment and problem solving, community affairs/involvement, and home life and hobbies categories are scored using a 5-point ordinal scale, as follows:  
–0 indicates no impairment  
–0.5 indicates very mild impairment  
–1 indicates mild impairment 
–2 indicates moderate impairment  
–3 indicates severe impairment  
The personal care category is scored using a 4 -point ordi nal scale, as follows:  
–0 indicates no impairment  
–1 indicates mild impairment 
–2 indicates moderate impairment  
–[ADDRESS_1020815] scoring sheet vary based on the category being evaluated; the selection criteria for each score are clearly described on the scoring sheet .  In the CDR -SOB scoring method, all 6 categories are weighted 
equally, and the scores for each of the categories are summed to obtain a total score; the total score can be [ADDRESS_1020816] 
subtleties in dementia severity and increased precision in serially tracking the severity of dementia.  SOB scores are used 
to rate dementia severity as follows:  
–0 indicates normal cognitive functioning 
–0.5–4.0 indicates questionable cognitive impairment  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 67 of 100  
- 0.5–2.5 indicates questionable impairment  
- 3.0–4.0 indicates very mild dementia  
–4.5–9.0 indicates mild dementia  
–9.5–15.5 indicate s moderate dementia  
–16.0– 18.0 indicates severe dementia  
 
References  
Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living 
for clinical trials in Alzheimer’s Disease. Alz Dis Assoc Disord. 1 997;11 (Suppl 2):S33- 39. 
 
O’Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. Staging dementia using Clinical Dementia 
Rating Scale Sum of Boxes scores: a [LOCATION_007] Alzheimer’s Research Consortium study. Arch Neurol. 2008;65:1091 -1095.  
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 68 of 100  
Appendix 4. Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS -ADL23)  
The ADCS -ADL 23 contains 23 items covering physical and mental functioning and independence in self -care.  For each ADL, an 
informant/trial partner is first asked if the patient attempted the activity during the past 4 weeks .  If a patient did attempt the ADL, the 
inform ant/trial partner is asked to choose the single most accurate definition of the patient’s level of performance .  The scores range 
from [ADDRESS_1020817] questions used for as sessment 
of mild to moderate AD.  
***************************************************************************** 
1. Regarding eating: Which best describes subjects’ usual performance during the past 4 weeks?  
  Ate without physical help  
  Used a fork or spoon, but not a knife to eat  
  Used fingers to eat  
  Usually or always was fed by [CONTACT_24663]  
2. Regarding walking (or getting around in a wheelchair), in the past [ADDRESS_1020818] describes his/her optimal performance:  
  Mobile outside of home without physical help  
  Mobile across a room without physical help  
  Transferred from bed to chair without help  
  Required physical help to walk or transfer  
3. Regarding bowel and bladder function at the toilet, which best describes his/her usual performance in the past 4 weeks:  
  Did everything necessary without supervision or help  
  Needed supervision, but no physical help, and was usually continent  
  Needed physical help, and was usually continent  
  Needed physical help, and was usually incontinent  
4. Regarding bat hing, in the past [ADDRESS_1020819] describes his/her usual performance:  
  Bathed without reminding or physical help  
  No physical help, but needed supervision/reminders to bathe completely  
  Needed minor physical help (e.g., with washing hair) to bathe completely  
  Needed to be bathed completely 
5. Regarding grooming, in the past [ADDRESS_1020820] describes his/her optimal performance:  
  Cleaned and cut fingernails, without physical help  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020821] his/her first set of clothes for the day?  
Yes / No / don't know - If Yes, which best describe s his/her usual performance:  
  Without supervision or help  
  With supervision  
  With physical help  
6b. Regarding physically getting dressed, which best describes his/her usual performance in the past 4 weeks (check one):  
  Dressed completely without supervision or physical help  
  Dressed completely with supervision, but without help  
  Needed physical help only for buttons, clasps, or shoelaces  
  Dressed without help if clothes needed no fastening or buttoning  
  Always needed help, regardless of type of clot hing 
  Don’t know 
7. In the past [ADDRESS_1020822] use a telephone  
Yes / No / don't know - If Yes, which best describes his/her highest level of performance:  
  Made calls after looking up numbers in white or yellow pages, or by [CONTACT_746298] -known numbers without referring to a directory, list, or preprogrammed numbers  
  Made calls only to well -known numbers by [CONTACT_2329] a directory or list  
  Answered the phone; did not make calls  
  Did not answer the phone, but spoke  when put on the line  
8. In the past [ADDRESS_1020823] watch television?  
Yes / No / don't know - If Yes, ask each of the following (Yes / No):  
          a. Did subject usually select or ask for different programs or his/her favorite show?  
          b. Did subject usually talk about the content of a program while watching it?  
          c. Did subject talk about the content of a program within a day (24 hours) after watching it?  
9. In the past [ADDRESS_1020824] 5 minutes?  
(note subject did not need to initiate the conversation)  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 70 of 100  
Yes / No / don't know - If Yes, which best describes his/her usual degree of participation:  
  Usually said things what were related to the topic  
  Usual ly said things that were not related to the topic  
  Rarely or never spoke  
10. Did subject clear the dishes from the table after a meal or snack?  
Yes / No / don't know - If Yes, which best describes how he/she usually performed:  
  Without supervision or hel p 
  With supervision  
  With physical help  
11. In the past [ADDRESS_1020825] usually manage to find his/her personal belongings at home?  
Yes / No / don't know - If Yes, which best describes how he/she usually performed:  
  Without supervision or help  
  With supervision  
  With physical help  
12. In the past [ADDRESS_1020826] obtain a hot or cold beverage for him/herself?  
Yes / No / don't know - If Yes, which best describes his/her highest level of performance:  
  Made a hot beverage, usually without physic al help  
  Made a hot beverage, usually if someone else heated the water  
  Obtained a cold beverage, usually without physical help  
13. In the past [ADDRESS_1020827] make him/herself a meal or snack at home?  
Yes / No / don't know - If Yes, which best desc ribes his/her highest level of performance:  
  Cooked or microwaved food, with little or no help 
  Cooked or microwaved food, with extensive help 
  Mixed or combined food items for a meal or snack, without cooking or microwaving (e.g., made a sandwich) 
14. In the past [ADDRESS_1020828] or container at home?  
Yes / No / don't know - If Yes, which best describes how he/she usually performed:  
  Without supervision or help  
  With supervision  
  With physical help  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020829] get around (or travel) outside of his/her home?  
Yes / No / don't know - If Yes, which best describes his/her optimal performance:  
  Alone, went at least [ADDRESS_1020830] ever go shoppi[INVESTIGATOR_007]?  
Yes / No / don't know - If yes, ask A and B  
A) Which one best describ es how subject usually selects items?  
  Without supervision or physical help  
  With some supervision or physical help  
  Not at all, or selected mainly random or inappropriate items  
B) Did subject usually pay for items without supervision or physical help?  
  Yes 
  No 
17. In the past [ADDRESS_1020831] keep appointments, meetings with other people, such as relatives, a doctor, the hairdresser,  etc.? 
  Usually remembered, may have needed written reminders, e.g., notes, a diary, or calendar  
  Only remembered the appointment after verbal reminders on the day  
  Usually did not remember, in spi[INVESTIGATOR_746255]  
18. In the past [ADDRESS_1020832] ever left on his/her own?  
Yes / No / don't know - If yes, ask all questions:  
Was subject left: 
     Yes / No  
          a) away from home for 15 minutes or longer, during the day?  
          b) at home for an hour or longer, during the day 
          c) at home, for less than [ADDRESS_1020833] talk about current  events? (This means events or incidents that occurred during the past month.)  
Yes / No / don't know - If yes, ask all questions:  
Did subject talk about events that (Yes / No):  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 72 of 100  
          a) he/she heard or read about or saw on TV but did not take part in?  
          b) he/she took part in outside home involving family, friends, or neighbors?  
          c) events that occurred at home that he/she took part in or watched  
20. In the past [ADDRESS_1020834] read a magazine, newspaper or book for more than 5 mi nutes at a time?  
Yes / No / don't know - If yes, ask all questions:  
Did subject usually (Yes / No):  
          a) talk about details of what he/she read while or shortly (less than 1 hour) after reading?  
          b) talk about what he/she read 1 hour or lo nger after reading?  
21. In the past [ADDRESS_1020835] ever write things down?  
Yes / No / don't know (Note: if subject wrote things only after encouragement or with help, the response should still be ‘Yes ’.) 
If yes, which best describes the most complica ted things that he/she wrote:  
  Letters or long notes that other people understood  
  Short notes or messages that other people understood  
  His/her signature [CONTACT_746307]  
22. In the past [ADDRESS_1020836] perform a pastime, hobby, or game?  
Yes / No / don't k now - If yes, how did subject usually perform his/her most common pastimes:  
  Without supervision or help  
  With supervision  
  With help  
  If subject performs hobbies/pastimes only at day care, check here  
23. In the past [ADDRESS_1020837] use a household appliance to do chores?  
Examples include washer, dryer, vacuum, dishwasher, toaster, toaster over, range, microwave, food processor  
Yes / No / don't know 
Reference:  
Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical 
trials in Alzheimer’s Disease . Alz Dis Assoc Disord. 1997;11 (Suppl 2):S33 -39. 
Questionnaire modified from electronic form developed at the Palo Alto Veterans Affairs Hospi[INVESTIGATOR_746256], M.D., Ph.D., Jerome Yesavage, 
M.D. Available at: http://www.medafile.com/cln/ADCSADLm.htm  
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 73 of 100  
Appendix 5 .  Alzheimer’s Disease Cooperative Study - Clinical Global Impression of Change (ADCS -CGIC)  
 
The ADCS -CGIC evaluates the patient in five treatment domains: 1) cognition (immediate and delayed memory, praxis, 
attention, and executive function); 2) clinical global change; 3) activities of daily living; 4) behavioral symptoms 
(agitation and other noncognitive symptoms); 5) cognition in severely impaired patients .   
Instructions for Administration of the ADCS -CGIC  
The ADCS -CGIC consists of two parts; Part I, the baseline evaluation (includes information from both the subject and 
informant); Part II, ADCS_CGIC forms for both subject and informant.  
The overall intent of the ADCS-CGIC is to provide a reliable means to assess global change from baseline in a clinical trial.  It provides a semi structured  format to  enable clinicians to gather necessary clinical information from both the 
patient and informant to make a global impression of change.  
Part I is used to record baseline information to serve as a reference for future ratings.  Part II is composed of two sections , a subject interview form and an informant interview form .  These forms are used to record information from 
separate interviews with both the subject and informant from which an impression of change score is made.  
Baseline Evaluation  
At baseline, the clinician interviews the patient and caregiver, recording onto Part I notes about baseline status for later 
reference.  At baseline only, clinical information about the subject from any source can be used .  The clinician indicates 
on a checkl ist the sources of information compi[INVESTIGATOR_124511].  
Parts I and II share a similar format for recording relevant clinical information .  The column headed “Area” identifies 
various areas that a clinician might consider while evaluating a patient for potential clinical change, including what might 
be expected to be assessed in performing an ordinary but brief comprehensive office interview to determine a subject’s baseline status and eligibility for a clinical trial.  The “Probes” column p rovides sample items that a clinician might find 
useful in assessing an area, and these are intended as guides for collecting relevant information .  The last column 
provides space for notes .  For the baseline form, there are separate spaces for notes taken  from the informant and patient 
interviews.  
There is no specified amount of time to complete the baseline form.  
 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020838]. 
After completing the interviews, the clinician records the clinical impression of change on a 7 -point Likert -type scale 
(from marked improvem ent to marked worsening) .  The ADCS -CGIC is a rating of change and not of severity .  The 
clinician may refer to the baseline data in Part I. The clinician, alone, must make decisions about change, without consulting other staff .  The clinician should avoid 
asking opi[INVESTIGATOR_124512], which may contaminate the ratings, such as opi[INVESTIGATOR_746257].  At the beginning of the interview, the clinician may wish to caution the informant to refrain from mentioning this infor mation.  
The time allotted for the subsequent ratings of change is [ADDRESS_1020839] or information interview .  This time 
was chosen on the basis of the mean time reported by [CONTACT_124552].  
 
References:  
Ferris SH, Mackell JA, Mohs R, Scheider LS, Galasko D, Whitehouse P, et al . A multicenter evaluation of new treatment 
efficacy instruments for Alzheimer’s disease clinical trials: overview and general results. Alz Dis Assoc Dis. 
1997;11(Suppl 2):S1-S12.  
Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg, B, et al. Validity and reliability of the Alzheimer’s 
Disease Cooperative Study -Clinical Global Impression of Change. Alzheimers Dis Assoc Disord 1997;11 (Suppl 
2):S22 -S52. 
 
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 75 of 100  
Appendix 6 .  Neuropsychiatric Inventory -Questionnaire (NPI- Q) 
 
The NPI -Q is designed to be a self -administered questionnaire completed by [CONTACT_746299].  Each of the 12 NPI -Q domains contains a survey question that reflects cardinal symptoms of that domain.  Initial 
responses to each domain question are "Yes" (present) or "No" (absent).  If the response to the domain question is "No", 
the informant goes to the next question.  If "Yes", the informant then rates both the Severity of the  symptoms present 
within the last month on a [ADDRESS_1020840] of the symptom manifestations on them (i.e. Caregiver 
Distress) using a [ADDRESS_1020841] the NPI-Q in part or entirely as an interv iew. 
Questions  
1. Delusions: Does the patient have false beliefs, such as thinking that others are stealing from him/her or planning to harm him/her in some way? 
2. Hallucinations: Does the patient have hallucinations such as false visions or voices? Does he or she seem to hear 
things that are not present?  
3. Agitation/Aggression: Is the patient resistive to help from others at times, or hard to handle?  
4. Depression/Dysphoria: Does the patient seem sad or say that he/she is depressed?  
5. Anxiety: Does the patient become upset when separated from you?  Does he/she have any other signs of nervousness such as shortness of breath, sighing, being unable to relax, or feeling excessively tense?  
6. Elation/Euphoria: Does the patient appear to feel too good or act excessively happy?  
7. Apathy/Indifference: Does the patient seem less interested in his/her usual activities or in the activities/plans of others? 
8. Disinhibition: Does the patient seem to act impulsively, for example, talking to strangers as if he/she knows them, or 
saying things that may hurt people’s feelings?  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 76 of 100  
9. Irritability/Lability: Is the patient impatient and cranky? Does he/she have difficulty copi[INVESTIGATOR_746258]?  
10. Motor Disturbance: Does the patient engage in repetitive activities such as pacing around the house, handling 
buttons, wrappi[INVESTIGATOR_746259], or doing other things repeatedly?  
11. Nighttime Behaviors: Does the patient awaken you during the night, rise too early in the morning, or take excessive naps during the day? 
12. Appetite/Eating: Has the patient lost or gained weight, or had a change in the type of food he/she likes? 
Reference:  
Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI -Q, a brief clinical 
form of the neuropsychiatric inventory. J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-239.  
 
  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 77 of 100  
Appendix 7 .  Savonix 8 Mobile Application: Overview  
 
Savonix Mobile is a battery of digitized neurocognitive assessments delivered via HIPPA and COPPA 
compliant Android and iOS mobile operating systems and  supported by a web-based client dashboard system for 
data tracking and analytics.   
 
Savonix Mobile provides a screening tool for m arkers of multiple domains of cognitive and emotional 
function that are impaired in a wide range of ment al health problems .  Savonix Mobile delivers tests that are 
capable of assessing function in 14 cognitive and emotional domains:  
• Verbal Memory (Immediate)  
• Verbal Memory (Delayed)  
• Impulse Control  
• Focus  
• Sustained Attention  
• Emotion Regulation  
• Emotion Recognition  
• Information Processing Speed 
• Cognitive Flexibility  
• Working Memory 
• Executive Function  
• Visual Spatial Memory  
• Decision Making (Risk Taking/Loss Aversion Scale)  
• Emotionality (Positivity/Negativity Bias)  
 
Features of Savonix Mobile  
Age-Gated and Color -Blind versions  
Modified versions of the Savonix Mobile accommodate children and color -blind individuals.  
 
Savonix Mobile Assessment Administration  
Within the application, users are presented with a short  demographics questionnaire to establish factors such as 
identity, gender, age and education level to provide normative/percentile scores in the results section.  A brief screen is 
presented that demonstrates how to take the Savonix Mobile assessment and gives the user instructions to follow to begin the assessment .  In addition to written instructions, audio instructions are available for the user to toggle on and 
off.   
User s are informed that they may take short breaks between tasks but may not exit the app until the entire assessment is 
complete.  
A practice condition precedes each task to give the user a chance to learn the interface before scoring begins.  Before each task, countdown screens are used to prepare the user to begin.  
 
Repeat Assessment  
Savonix Mobile uses parallel forms of configurable tasks as a built- in method for controlling for practice effects 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020842] is not 
repeated for the same user.   
 
Savonix Mobile Task  Parallel Forms  
Verbal Memory Recognition  3 
Go / No -Go Task  Randomized  
Verbal Interference  Randomized  
N-back Task  Randomized  
Emotion Identification  Randomized  
Trailmaking Task  6 
Maze Task  6 
Complex Figure Copy  3 
Digit Span  Randomized  
 
Reporting  
Scores will be provided directly to the CRO for data analysis via a CSV file that includes each user’s demographic 
information, performance across domains on each administration of Savonix Mobile, raw trial-by- trial data, as well 
as descriptive means and v ariances of response times, correct and incorrect responses, and completion times for 
applicable tasks .  Scores will not be available to subjects or study staff .  To support quality data collection, 
statistics regarding whether tests were completed or not will be provided to study staff on an ongoing basis.  
 Description of Savonix Mobile Tasks 
Verbal Memory Recognition Task  
This task measures immediate and delayed verbal learning .  Users are presented with a list of words, which they are 
asked to memorize and later recognize from memory .  Words are closely matched on concreteness, length, and 
frequency of use .  After the memorization period, the user is asked to recognize as many words from the list as possible 
from a series of words, comprised of listed words and foil words .  A delayed memory recognition trial is completed 
approximately 30 minutes later after a number of intervening tasks .  The outcome variables are the number of words 
correctly and incorrectly recognized across the immediate and delayed trials.  
 
Go / No -Go Task  
This task measures impulse control .  A green circle is presented frequently (Go) and a red square infrequently (No -Go) 
on the screen .  The user is required to inhibit the screen tap responses on the square and tap quickly on the circle when 
presented .  This task measures target detection rate; response time and errors of commission and omission .  It is used to 
assess the capacity for suppressing well -learned, automatic responses.  The outcome variables are the number correct and 
incorrect responses, and response times for correct and incorrect responses.  
 
Verbal Interference Task  
This task taps the ability to inhibit automatic and irrelevant responses as a measure of focus.  The user is presented with colored words, one at a t ime.  Each word is drawn from the following set of words: red, yellow, green and blue .  Below 
each colored word is a response pad with the four possible colors displayed in black and in fixed format .  The test has 
two parts.  In trial 1, the user is requir ed to identify the name [CONTACT_746308] .  In trial 2, the user is 
required to name [CONTACT_746309] .  Each part lasts for 1 minute.  
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020843] to remember the position of the item TWO 
turns back, and so on .  A 1 -back is used in the child’s version of the assessment, and a [ADDRESS_1020844] of emotional recognition.  Users are presented with a series of faces with different emotional expressions (i.e. 
surprise, fear, disgust, happy, sad, neutral).  Users tap a button on the touch screen to correctly match the name [CONTACT_746310].  The goal is to identify the correct emotional expression presented by [CONTACT_746300].  The outcome variable is the total correct versus incorrect and the response time for each face presented.  
 
Trail M aking Task  
Part 1 of this task is a measure of visual scanning and information processing speed.  The user is presented with a pattern 
of 13 numbers (1-13) on the screen and is required to touch numbers in ascending sequence (i.e., 1, 2, 3…) .  As each 
number is touched in correct order, a line is drawn automatically to connect it to the preceding number or letter in the 
sequence.  This allows the user to visualize t he path touched.  The outcome variable is time to completion as well as 
number of correct responses versus incorrect responses.  
Part 2 of this task is a measure of cognitive flexibility and attention switching.  The user is presented with a pattern of 13 
numbers (1-13) and 12 letters (A -L) on the screen and is required to touch numbers and letters alternatively in ascending 
sequence (i.e.  1, A, 2, B, 3, C...).  As each number or letter is touched in correct order, a line is drawn automatically to 
connect it to the preceding number or letter in the sequence .  This allows the user to visualize the path touched .  The 
outcome variable is time to completion as well as number of correct responses versus incorrect responses in comparison 
with results from Trail M aking Part 1.  
 
Maze Task  
This task is used as a measure of working memory and executive function .  The user is presented with a 6x6 grid of tiles 
on the device screen .  The object of the task is to identify the hidden path through the grid, from the beginning point at 
the bottom of the grid to the end point at the top.  The user is able to navigate around the grid by [CONTACT_53737][INVESTIGATOR_746260].  The hidden path must be discovered in order by [CONTACT_53737][INVESTIGATOR_746261] .  A total of [ADDRESS_1020845] 
moves are required to complete the maze.  The user is presented with a green “check mark” if they make a correct move, 
red “x” if they make an incorrect move, and a blue “?” if they have tapped out of order .  The task serves to assess how 
quickly the  user learns the route through the maze and their ability to remember that route.  One maze is presented across 
two trials to assess for learning between trials.  The outcome variable is the total number of correct responses versus 
errors and time to compl etion.  
 
Complex Figure Copy Task 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page [ADDRESS_1020846] sequence lengths correctly 
completed forwards and backwards.   
 
Additional Reading  
 
Clark CR, Paul RH, Williams LM, Arns M, Fallahpour K, Handmer C, et al. Standardized assessment of cognitive 
functioning during development and aging using an automated touchscreen battery. Arch Clin Neuropsychology. 
2006;21:449-467.  
Mathersul D, Palmer D, Gur R, Gur R, Cooper N, Gordon E, et al. Explicit identification and implicit recognition of 
facial emotions: II. Core domains and relationships with general cognition.  J Clin Exp Neuropsych. 2009;31(3):278-
291.  
Paul RH, Haqu e O, Gunstad J, Tate DF, Grieve SM, Hoth K, et al. Subcortical hyperintensities impact cognitive 
functio n among a sele ct subset of he althy elderly. Ar ch Clin Neuropsych. 2005; 20(6): 697- 704. 
Paul RH, Gunstad J, Cooper N, W illiams LM, Clark R, Cohen RA, Lawrence JJ, et al. Cross-cultural assessment of 
neuropsychol ogical performance and el ectrical brain function measure s: addition al validation o f an International 
brain d atabase. Int J Neurosci.  2007; 117:549- 568. 
Rowe D L, Cooper NJ, Liddell BJ, Clark RC, Gordo n E, Williams LM. Brain  structure and func tion correlates of 
Gene ral and S ocial Cognition. J Integ Neurosci.  2007; 6(1): 35-74. 
Williams L, Mathersul D, P almer D, Gur R, Gur R, Gordon E. Explicit ident ification and implicit recognition of faci al 
emotion s:  I. Age effects in males and fem ales across 10 decades. J Clin Exp Neurospsych. 2009;31:257- 277. 
 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 81 of 100  
Appendix 8 .  Columbia Suicide Severity Rating Scale (C -SSRS) 
 
 
 

 
Protocol# ALK6019-201   v7.0 02NOV2018 
 
_________________________________________________________________                                    _________ 
CONFIDENTIAL/PROPRIETARY  Page 82 of 100  
 
  
 
      
 
     
 
      

 
Protocol# ALK6019-201   v7.0_02NOV2018 
 
 
17 SCHEDULE OF EVENTS 
 
 
 

 
Protocol# ALK6019-201   v7.0_02NOV2018 
 
 
Notes:  *To be performed during screening period after all other criteria have been met. Transthoracic echocardiogram and MRI may be 
performed in either order, but prior to the optional PET Scan. The optional PET Scan should only be performed after all screening 
procedures have been completed, and the subject meets criteria for inclusion . 
  X1: to be performed prior to infusion start. 
  X2: to be performed after infusion . 
  a: Screening, Baseline, and EOS /ET visits may be split to allow for sufficient time to complete all procedures. AEs and concomitant 
medications should be reviewed during split visits, as applicable.  
  b: The treatment window is 5 + 1 days. If study treatment is administered over a period of 6 days, then Visits 8 and/or 16 may occur 1 
day later. The visit window for Visit 11 is Day 85 ± 7 days; visits 12 -16 should follow consecutively.  
  c: includes all comprehensive labsf, infectious serology (HIV, hepatitis B, hepatitis C), cobalamin (vitamin B12) level, pyridoxine 
(vitamin B6) level, thiamine (vitamin B1) level, thyroid -stimulating hormone (TSH) level, direct antiglobulin test, RBC antibody 
screen, brain natriuretic peptide (BNP), serum IgA, haptoglobin, and C1 inhibitor.  
Urine drug screen: cannabinoids, benzodiazepi[INVESTIGATOR_050], barbiturates , opi[INVESTIGATOR_858], cocaine, amphetamines, methadone, phencyclidine. 
Urinalysis: urine protein, UPCR.  
  d: includes all comprehensive labsf, infectious serology, direct antiglobulin test, RBC antibody screen.  
  e: Samples for i-STAT labs should be collected and results interpreted PRIOR to infusion start. Using i -STAT Chem -8+ cartridge: 
sodium ( Na), potassium  (K), chloride (Cl), total carbon dioxide (TCO 2), anion gap, ionized calcium, glucose, urea nitrogen  
(BUN)/urea, creatinine (Crea), hematocrit, hemoglobin.  
  f: comprehensive labs: alkaline phosphatase (ALP), ALT (SGPT), amylase, AST (SGOT), bicarbonate, bilirubin (direct, indirect,  and 
total), ionized calcium, chloride, cholesterol, low -density lipoprotein (LDL), high -density lipoprotein (HDL), creatinine kinase (CK or 
CPK), creatinine, gamma- GT (GGT), glucose (random), iron, lactate dehydrogenase (LDH or LD), lipase, magnesium, phosphat e, 
potassium, protein total, sodium, triglycerides, blood urea nitrogen (BUN), eGFR, albumin, aPTT, PT, INR, complete blood count 
(CBC) with differential (basophils, eosinophils, lymphocytes, monocytes, neutrophils).  
Urinalysis: blood, glucose, ketone, protein, pH, specific gravity, nitrite, leukocytes, bilirubin, urobilinogen, urine creatinine, urine 
albumin, albumin/creatinine ratio, urine sodium, sodium/creatinine ratio, urine potassium, potassium/creatinine ratio, and re flex urine 
microscopy if indicate d. 
  g: interim safety labs: blood creatinine, BUN, eGFR . Note: Subjects randomized prior to August 30, 2018, will not participate in the 
additional interim safety labs at Visit 9 and Visit 17.  
  h: Window for completing the MRI is Visit 8 + 4 days.  
  i: In consenting, eligible subjects, the optional lumbar puncture should be performed at any time during the Baseline Visit w indow. 
The second (final) lumbar puncture should be performed within 5 days following the final dose.  
 
 
 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 85 of 100   
18 REVISION HISTORY  
Protocol Version 7.0 dated 02NOV2018 
Replaces: Protocol Version  6.0 dated 12OCT2018 
In this table , changes from Version 6.0 dated 12OCT2018 are described and their rationale is given. 
Location  Description  Purpose  
Throughout  Protocol Version previously read : 
v6.0_12OCTMAR2018  
 
Now reads : v7.0_ 02NOV [ADDRESS_1020847] of 
Definitions, 
Protocol Summary  The Infusion Period will be now be  between  2 hours to 
a maximum of 3 hours.  The Infusion Period was previously 
increased to from 2.0 to 2.5 hours to 2.5 to 3 hours; to maintain blinding and continuity, all patients will now be infused between 2 hours to a maximum of 
3 hours.  
Protocol 
Summary, 4.1 
Description of 
the Study 
Design  Extension of study duration to ~19 months was 
reverted to ~15 months and recruitment period of ~12 
months was reverted to ~[ADDRESS_1020848] revised 
dosing.  Required changes  
 
7.3.3 
Randomization, 
10.5 Sample Size The following sentence was added to both sections, 
“Subjects who are randomized but do not receive any 
dose of the study agent, may be re -screened and 
randomized if they meet all of the study eligibility 
requirements. ” Content added to clarify potential re -
screening for eligible subjects. 
17 Schedule of 
Events  Note “c”: removed propoxyphene from urine drug 
screen.  Screening for this substance is not 
required.  
 
 
  

 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 86 of 100   
Protocol Version 6.0 dated 12OCT2018 
Replaces: Protocol Version  5.0 dated 30AUG2018 
In this table , changes from Version 5.0 dated 30AUG2018 are described and their rationale is given. 
Location  Description  Purpose  
7.3 Study 
Schedule / 
17 Schedule of Events  • Amended the Study Schedule and Schedule of Events 
to includ e i-STAT labs on V4, V6, V8, V 12, V14, and 
V16. 
• Amended the Study Schedule and Schedule of Events to include the following per Clarification Memo #4: “Note: su bjects randomized prior to August 30, 2018, 
will not participate in the additional interim safety labs at Visit 9 and Visit 17.” • Added i-STAT lab  evaluations for 
increased  safety monitoring  after 
FDA request . 
• Per Protocol V5.0 (30AUG2018), 
blood samples are to be collected at Visit [ADDRESS_1020849] 30, 2018, will not participate in the additional interim safety labs at Visit 9 and Visit 17  since they will be following 
the previous protocol version .  
 
Protocol Version 5.0 dated 30AUG 2018 
Replaces: Protocol Version  4.0 dated 2 7MAR 2018 
In this table , changes from Version 4.0 dated 27MAR 2018 are described and their rationale is given. 
Location  Description  Purpose  
Title Page, Protocol 
Approval Page, 1.1 Authorized Representative (Signatory) / 
Responsible Party  Updated Sponsor’s mailing address and 
authorized representative.  Administrative.  
Throughout  Protocol Version Previously read : 
v4.0_ 27MAR2018  
 
Now reads : v5.0_30AUG2018  Version control.  
  
 
 
 
   
 
 
  

 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page [ADDRESS_1020850] of Definitions / 
Protocol Summary  Extended the Infusion Period to be a maximum 
of 3 hours.  Infusion rates will be adjusted such that 
the Infusion Period will be of 
approximately the same duration for all 
doses (e.g., 100 mL, 250 mL,  
). 
Protocol Summary, 
4.2.2 Secondary Endpoints, [IP_ADDRESS] 
Procedures to Assess 
Safety  Moved the following from list of exploratory 
endpoints to secondary safety endpoints: “Changes on MRI scans designed to assess for 
Amyloid Related Imaging Abnormalities 
(ARIA)” and updated other sections of the 
Protocol accordingly.  Evaluating changes on MRI scans to 
assess for ARIA is a secondary safety endpoint.  
Protocol Su mmary, 4.1 
Description of the 
Study Design  Extended study duration to ~[ADDRESS_1020851] one dose of GRF6019 but 
withdraw/terminate from the study early may be 
invited to complete the end of study procedures.  
 To clarify that end of study procedures do 
not need to be completed for subjects who 
terminate from t he study prior to initial 
dosing (e.g. Visit 3).  
5.1 Inclusion Criteria, 
[IP_ADDRESS].[ADDRESS_1020852] a systolic ejection fraction that is greater than or equal to 55% and no other 
clinically significant abnormalities are noted.  Unless there is evidence of cardiac 
pathology on echocardiography, an elevated ejection fraction is not a safety concern.  Echocardiography will be used 
at screening to exclude subjects with an 
ejection fraction of less than 55% and 
subjects with other echocardiographic abnormalities, including impaired diastolic function (e.g. impaired diastolic relaxation) or hypertrophic 
cardiomyopathy .   
5.2 Exclusion Criteria  Previo usly read :  
• Heart disease (or history thereof), as evidenced by [CONTACT_97123], unstable, new onset or severe angina, or 
congestive heart failure ([LOCATION_001] 
Association Class II, III or IV) in the 6 months prior to dosing; uncontrolled high blood pre ssure (systolic blood pressure of 
160 mmHg or higher and/or diastolic blood 
pressure of 100 mmHg or higher) despi[INVESTIGATOR_746262] 3 months prior to Protocol clarity and standardization.  
 
Addition of exclusion criterion for 
subjects with treatment -refractory 
hypertension because such subjects may 
be more likely to experience a hypertension during GRF6019 infusions.  

 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 88 of 100   
Location  Description  Purpose  
dosing.  
 
Now reads:  
• Heart disease , including myocardial 
infarction, unstable, new onset or severe 
angina, or congestive heart failure (New 
York Association Class II, III or IV) in the 6 months prior to dosing;  
• Poorly  controlled high blood pressure 
(systoli c blood pressure of 160 mmHg or 
higher and/or diastolic blood pressure of 100 mmHg or higher) despi[INVESTIGATOR_746263] [ADDRESS_1020853] on cognition, therefore concurrent use is allowed.  
5.2 Exclusion Criteria  Previously read : Any major psychiatric 
disorder including psychosis, claustrophobia, major depression or bipolar disorder, and/or 
alcohol/substance dependency.  
 
Now reads: A history of a  major psychiatric 
disorder diagnosed before the onset of AD,  
including schizophrenia , major depression or 
bipolar disorder, and/or alcohol/substance dependency.  Psychiatric symptoms that occur 
in the context of AD (e.g. psychosis, irritability, 
depressio n) are not exclusionary unless the PI 
[INVESTIGATOR_746264].  Protocol clarity and standardization.  
5.4.1 Reasons for 
Withdrawal or 
Termination  Removed the following bullet point: “Treatment 
with a prohibited concomitant medication other than the use of appropriate medications for the treatment of AEs under direction of the 
investigator.”  Treatment with a prohibited concomitant 
medication will be considered on a case-by-case basis as a reason for withdrawal or termination, but not result in automatic 
subject withdrawal.  
5.4.1 Reasons for 
Withdrawal or 
Termination  Removed “or change in trial partner” to reflect 
Protocol Clarification Memo #3.  Protocol clarity and standardization.  
5.5 Premature 
Termination or Amended to state that the Sponsor reserves the 
right to terminate the study at any time and To clarify that the Sponsor, not the 
inves tigator, may terminate the study; 
 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page [ADDRESS_1020854] of potential 
reasons for study or site termination.  investigators may terminate the study at 
their site at any time.  
[IP_ADDRESS] Screening 
Procedures, [ADDRESS_1020855] been completed.  To enhance feasibility, as the sequence of 
these procedures is inconsequential.  
[IP_ADDRESS].1 Review of 
Adverse Events 
 Previously read : AEs will be reviewed, 
documented, and reported as required at each 
visit, beginning at baseline.   
 
Now reads: AEs will be reviewed, documented, 
and reported as required at each visit . Modified to reflect that AEs and 
concomitant medications may need to be assessed during split screening visits, as applicable.  
3 Objectives and 
Purpose, [IP_ADDRESS].13  
Magnetic Resonance Imaging, [IP_ADDRESS] Magnetic Resonance 
Imaging  Amended to reflect Protocol Clarification 
Memos #1 and #2.  Protocol clarity and standardization.  
7.3 Study Schedule  Previously read : Visit windows (when noted) 
should be benchmarked relative to the baseline visit for a subject, such that subjects complete the entire study by [CONTACT_2006] 168 (±7 days).  
 
Now reads: Visit windows (when noted) should 
be benchmarked relative to Visit [ADDRESS_1020856], 
such that subjects complete the entire study by 
[CONTACT_2006] 168 (±7 days).  Protocol clarity; Visit 3 corresponds to 
Day 1.  
7.3.1 Screening, 17 
Schedule of Events  Clarified that AEs and concomitant medications 
should be collected during split visits, as 
applicable.  Protocol clarity and standardization.  
7.3.4. Treatment, 17 
Schedule of Events  Added a ± [ADDRESS_1020857] been detected during the dosing period. Therefore, the frequency of pre -infusion 
i-STAT lab moni toring has been reduced 
to every other day during each dosing 
period.  
7.3.5 Follow -Up, 17 
Schedule of Events  Added interim safety labs (blood creatinine, 
blood urea nitrogen, and glomerular filtration 
rate) at Visits 9 and 17.  To more precisely evaluate p otential 
changes in creatinine levels kidney 
function over time.  
8 Assessment of Safety  Amended the Safety Section to clarify reporting For protocol clarity  and standardization.  
 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 90 of 100   
Location  Description  Purpose  
requirements for SAEs, AESI, and pregnancy.  
8.2.2 Relationship to 
Study Agent  Previously read : Final assessment of causality 
will be made by [CONTACT_1034] . 
 
Now reads: If either the investigator or the 
Sponsor considers the event related, then the 
event will be considered related for reporting 
purposes.  Sponsor decided to use a more 
conservative approach to causality 
determination. 
8.4.[ADDRESS_1020858]  Previously read : 
• AEs related to increased blood volume or 
shifts of fluid between the intravascular and extravascular space  
• Suspected transmission of blood- borne 
infectious agents 
 Now reads:  
• Clinically-significant peripheral edema or 
pulmonary edema.  
• Systolic blood pressure (BP) <90 or >160 
mm Hg and/or diastolic BP <60 or >100 
mm Hg, or a change of >25% from Day 1 
(Visit 3) pre-infusion in systolic and/or 
diastolic BP.   
• Reduced kidney function (eGFR < 45 
mL/min/1.73 m2).  
• Suspected transmission of bl ood-borne 
infectious agents . Protocol clarity and standardization.  
8.5 Study Halting 
Rules  Modified to state that if a Safety Evaluation 
Meeting is triggered, dosing may be temporarily 
halted.  Depending on the reason for the Safety 
Evaluation Meeting, dosing may or may 
not need to be halted.  
9 Clinical Monitoring  Minor updates and clarifications.  To align with study plans and processes.  
10.4.5 Adherence and 
Retention Analyses  Removed the “overall trial partner survey” as a 
measure of feasibil ity. Currently, there is no plan to administer 
an overall trial partner survey as an 
assessment of feasibility.  
12.3.1 Consent /Assent  
and Other Informational 
Documents Provided to 
Participants  Removed CSF Consent Form (optional).  A separate ICF has not been utilized.  
Rather, the main ICF includes a description of the optional CSF collection 
procedure and a separate signature [CONTACT_746311]/LARs to provide informed 
consent for the optional procedure.   
13.3 Protocol 
Deviations  Amended the definitions of Major and Minor 
Protocol Deviations.  Modified to align with Sponsor’s 
definitions.  
[ADDRESS_1020859] recent 
versions : Alzheimer’s Association  2018,  Administrative.  

 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 91 of 100   
Location  Description  Purpose  
 
 
 
 
Protocol Version 4.0 dated 27M AR2018 
Replaces: Protocol Version  3.[ADDRESS_1020860] and specialty lab specimen 
preparation, handling, storage, and 
shippi[INVESTIGATOR_746265].  
7.3 Study 
Schedule / 17 Schedule 
of Events  Amended the Study Schedule such that STAT labs will only 
be performed on V3-6, V8, V1 1-14, and V16.  Removed  the STAT labs on V7/V15 to 
reduce subject burden without compromising safety.  
Throughout  Clarified that the optional CSF collection will only be 
performed at participating sites.  For protocol clarity , as not all sites will 
perform this optional procedure.  
Throughout  Changed a ll reference s to the GRF6019 Infusion 
Administration Guidelines to reflect the actu al document 
title: Infusion Administration Manual.  For protocol clarity.  
Throughout  Protocol Version Previously read : v3.1_21FEB2018  
 
Now reads : v4.0_27MAR2018  Version control.  
 
Protocol Version 3.1 dated 21FEB2018 
Replaces: Protocol Version  3.0 dated 16FEB2018 
In this table , changes from Version 3.0 dated 16FEB2018 are described and their rationale is given.  
Location  Description  Purpose  
5.2 Exclusion 
Criteria Previously read: Clinically significant abnormalities 
on screening electrocardiogram (ECG) including QTc 
intervals (using Fridericia’s correction formula) of ≥ Modified to be less restrictive.  

 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 92 of 100   
Location  Description  Purpose  
430 ms in men and ≥ 4 50 ms in women.  
 
Now reads: Clinically significant abnormalities on 
screening electrocardiogram (ECG) including QTc intervals (using Fridericia’s correction formula) of ≥ 
450 ms in men and ≥ 470 ms in women . 
7.3 Study Schedule / 
17 Schedule of 
Events  Extended the visit window for Visit 8 MRI, such 
that the MRI may be performed at Day 6 + 4 days.  To enhance proto col feasibility.  
Throughout  Protocol Version Previously read : 
v3.0_16FEB2018  
 
Now reads : v3.1_21FEB2018  Version control.  
 
Protocol Version 3.0 dated 16FEB2018 
Replaces: Protocol Version  2.[ADDRESS_1020861] of Definitions  Specified that the Outcomes Assessor is responsible for 
monitoring subjects before, during, and after the infusion 
period.  For p rotocol clarity  and 
standardization.  
5.1 Inclusion 
Criteria Previously read : Willing to spend up to 6 nights in an 
inpatient study observation unit during both dosing periods.  
 
Now reads: Willing to spend up to [ADDRESS_1020862] 6 months will be excluded from the trial  for safety 
reasons .   
5.2 Exclusion 
Criteria Previously read : Prior hypersensitivity reaction to  any 
human blood product or intravenous infusion; any 
known drug allergy.  
 
Now reads: Prior hypersensitivity reaction to any human 
blood product or intravenous infusion; any known 
clinically significant  drug allergy.  Modified to be less restrictive , such 
that subjects with drug allergies 
deemed not clinically significant who 
meet all other eligibility criteria may 
be enrolled.  
7.3.3 Added s ection to the Study Schedule so that To allow sites flexibility as to when 
 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 93 of 100   
Randomization  randomization may occur any time after 
confirmation of eligibility (following Baseline) but 
prior to the subject’s first infusion on Visit [ADDRESS_1020863] to treatment who 
discontinues/withdraws prior to Visit 3.  randomization occurs.   
 
7 Study 
Procedures and 
Schedule  / 17 
Schedule of 
Events  UPCR to be performed at screening ONLY. Added 
the following urine tests as part of comprehensive 
labs: albumin/creatinine, sodium/creatinine, and 
potassium/creatinine. Removed stat urinalysis and 
amended the tests performed as part of the 
urinalysis for comprehensive labs.   Added additional testing for safety. 
Determined that stat urinalysis would not be necessary for guiding dosing decisions.  
7 Study 
Procedures and 
Schedule / 17 
Schedule of 
Events  Added a t argeted physical exam prior to dosing on 
Visits 3 -7 and 11-15; and prior to discharge on V8 
and V16. To assess for safety . 
7 Study 
Procedures and Schedule / 17 Schedule of 
Events  Fasting lab samples are preferred  for all visits 
except screening ; amended the order of procedures 
on applicable visits accordingly.  Fasting samples are preferable for 
proteomics.  
7 Study 
Procedures and Schedule / 17 Schedule of 
Events  Added ECGs to V7 (after dosing ), V11 (prior to 
dosing), and V15 (after dosing) .  To assess for safety .  
7 Study 
Procedures and Schedule / 17 
Schedule of 
Events  Added weight measurements prior to dosing on 
Visits 3 -7 and 11-15; and prior to discharge on V8 
and V 16. To assess  for fluid retention during 
dosing based on changes in weight . 
7.3 Study 
Schedule / [ADDRESS_1020864] -
inpatient. 
7 Study 
Procedures and 
Schedule  Where applicable, added a note indicating that the 
NPI-Q may be completed by [CONTACT_746301].  To enhance protocol feasibility.  
7.3 Study 
Schedule / 17 
Schedule of 
Events  Added ADCS -ADL to Visits 9 and 17 . To assess activities of daily living at 
additional timepoints.  
7.3 Study Added visit window for Visit 8 MRI, such that the To enhance protocol feasibility . 
 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 94 of 100   
Schedule / 17 
Schedule of 
Events  MRI may be performed at Day 6 + [ADDRESS_1020865] for Adults 
(Conventional Units) calculator.  To provide a resource for calculating 
MDRD.  
16 Appendices  Added a preface to the Appendices that reads : 
Please be advised that the neurocognitive assessments in this section and associated information are provided as EXAMPLES ONLY.  The actual neurocognitive assessments, related source documents, and instructions for administration and scoring are included in the Rater 
Reference Manual.   
  To clarify that the Appendices should 
not be the primary source of reference for performing the neurocognitive 
assessments.  Rather, all essential documents, materials, and instructions are provided in the Rater 
Reference Manual which is 
maintained separately from the 
protocol.  
Throughout  Previously, subjects would receive the infusion at a 
standardized flow rate.  As a result, the interval for 
administering 100 mL was shorter than the interval for 
administering the 250 mL dose.  To maintain blinding, 
all subjects would remain connected to the IV apparatus for a set period of time.  
 
The Infusion Period has been modified so that  all 
subjects, regardless of dose level, will receive their assigned dose over the course of  2 – 2.[ADDRESS_1020866] eligibility.  The C -SSRS will be 
repeated following each dosing 
interval but prior to discharge to 
evaluate for safety.   
Throughout  Clarified testing schedules for the  Savonix full and 
brief batteries.  Updated Schedule of Events accordingly. The brief battery will be performed at 
the start of the infusion visits.  The full battery will be performed at all 
other visits, beginning at Baseline.  

 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 95 of 100   
 
Protocol Version 2.0 dated 09NOV2017 
Replaces: Protocol Version  1.0 dated 02AUG2017 
In this table, changes from Version 1.0 dated 02AUG2017 are described and their rationale is given. 
Location  Description  Purpose  
Throughout  Protocol Title Previously read:  An Open Label, Multiple -
Dose Study to Assess the Safety and Tolerability of 
GRF6019 Infusions in Subjects with Mild to Moderate Alzheim
er’s Disease (AD)  
 Now reads: A Prospective, Randomized, Double -Blind, 
Dose-Comparison Concurrent Control Study to Assess the 
Safety and Tolerability of GRF6019 Infusions in Subjects 
with Mild to Moderate Alzheimer’s Disease (AD)  
 Updated study design 
pursuant to direction from the agency  
Throughout  Update of study design description from an open label 
multiple dose study to a prospective, randomized, double -
blind dose comparison concurrent control study  
 Updated study design 
pursuant to direction from the agency  
Throughout  Protocol Version Previously read:  v1.0_02AUG2017  
 
Now reads: v2.0_09NOV2017  
 Version Control  
Throughout  Grammar and style changes  For protocol clarity and 
standardization  
Throughout  Update duration of treatment to be approximately  [ADDRESS_1020867] of Definitions for Infusion Nurse, Infusion Period and 
Outcomes Assessor  
 For clarity of updated study 
design pursuant to direction 
from the agency  Throughout  Added Cerebrospi[INVESTIGATOR_17106] (CSF) biomarker 
analysis as an exploratory aim. Added CSF 
collection as an optional procedure. Amended 
applicable sections of the Protocol  accordingly.  To assess potential therapeutic effects 
of GRF6019 on AD biomarkers of neurona l death, synaptic function, 
inflammation, and growth factors.  
Throughout  Protocol Version Previously read : 
v2.0_09NOV2017  
 
Now reads : v3.0_ 16FEB2018  Version Control . 
Throughout  Grammar and style changes  For protocol clarity and 
standardization . 
 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 96 of 100   
Location  Description  Purpose  
Protocol 
Summary/Precis  Measures added to ensure adequate allocation concealment .  
Paragraph 3 added to summarize the infusion process and 
methods for blinding during infusion.  
 Updated study design 
pursuant to direction from the  
agency  
2.2 Rationale, 
Paragraph 8  Previously read:  An open -label, two -arm study design has 
been selected to identify a safe and feasible dosing 
paradigm, trends in changes of neurocognitive endpoints, 
and potential plasma derived factors that may affect these 
parameters.  
 
Now reads:  A prospective, randomized, double -blind, 
dose-comparison concurrent control  study design has been 
selected to  reduce or eliminate bias while facilitating the 
identification of  a safe and feasible dosing paradigm, trends 
in changes of neurocognitive endpoints, and potential plasma derived factors that may affect these parameters. 
 Updated study design 
pursuant to direction from the 
agency  
2.2 Rationale, 
Paragraph 9  Previously read:  … the results (of this trial) are 
nevertheless expected to lay the foundation for larger trials exploring  the potential benefit of GRF6019 in AD and 
other neurodegenerative disorders typi[INVESTIGATOR_746266].  
 
Now reads:  … the results (of this trial) are nevertheless 
expected to lay the foundation for larger trials designed and 
powered to characterize the potential benefits of GRF6019 
in AD and other neurodegenerative disorders typi[INVESTIGATOR_746232].  
 Clarificat ion of purpose of 
study design pursuant to 
direction of the agency 
3. Objectives and 
Purpose  Previously read:   As an exploratory objective, serial 
compositional analysis of subject plasma will be performed 
to identify specific biomarkers…  
 
Now reads:  As an exploratory objective,  blood and plasma 
will be collected and analyzed  to identify specific 
biomarkers…  
 Improved protocol clarity  
4.2.2 Secondary 
Endpoints, Paragraph 1  Confirmation that “This study is neither designed nor 
powered to detect statistically  significant differences in 
cognitive and motor outcomes…” 
 Clarification of purpose of 
study design pursuant to direction of the agency 
4.2.2 Secondary 
Endpoints  Addition of secondary feasibility endpoint related to 
success of blinding  Updated study design 
pursuant to direction from the 
agency  
4.2.3 Exploratory 
Endpoints  Previously read:   Cellular samples will be recovered from 
subject’s plasma  to explore epi[INVESTIGATOR_14364].  Improved protocol clarity  
 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 97 of 100   
Location  Description  Purpose  
 
Now reads:  DNA will be extracted from blood samples to 
explore epi[INVESTIGATOR_14364] .  
 
5.3 Strategies for 
Recruitment and 
Retention, 
Paragraph 4  Clarification that if a trial partner does not reside within a 
reasonable distance from the inpatient facility , they will be 
given the option to stay with the subjects or to stay in a 
nearby [CONTACT_746272]/motel.  Improved protocol clarity  
5.4.[ADDRESS_1020868] 
Storage and Stability  Previously read:   Partially used vials must be discarded.  
Vials which are cracked or have been previously entered or damaged should not be used, as this may have allowed the 
entry of microorganisms.  
 Now reads:  Vials which are cracked or have been 
previously entered or damaged should not be used, as this may have allowed the entry of microorganisms.  
 Correction  to enable drug 
accountability  
6.1.4 Preparation  Added: IV tubing should be vented,  
  
 Clarification  
6.1.5 Dosing 
Administration  Measures added to ensure adequate allocation concealment.  
Section updated to include provisions for the management and maintenance of study blinding during dosing, including the use of unblinded Infusion Nurses and blinded Outcomes Assessors.   
 
Administra tion Guidelines changed from Appendix 9 to a 
stand -alone manual . 
 Updated study design 
pursuant to direction from the 
agency  
6.2 Study Agent 
Accountability Measures added to ensure adequate allocation concealment. 
Addition and explanation of the role of unblinded study staff (study pharmacist, Infusion Nurse, CRA) in accountability of the study agent .   
 Updated study design 
pursuant to direction from the agency  
[IP_ADDRESS].3 Vital 
Signs  Previously read:   Vital signs will be collected at every visit 
and at multiple time points during the infusion (Appendix 9). 
 
Now reads:  Vital Signs will be collected at every visit.  During 
infusions, vital signs will be collected within an hour of infusion 
start, every 15 minutes during the ~2.5 hour infusion period, and 
at 3 and 6 hours following conclusion of the infusion period .  Updated for clarity of study 
procedures .  Updated for 
study design pursuant to 
direction from the agency  

 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 98 of 100   
Location  Description  Purpose  
Vital signs will be colle cted by [CONTACT_746302] .    
 
[IP_ADDRESS].[ADDRESS_1020869] should begin no 
later than one hour after starting the infusion.  Improved protocol clarity  
[IP_ADDRESS] P ET; 
7.3.1 Screening, 
Visit 1  Section updated to remove use of specific radioligand 
(Florbetapir) for PET testing.  Any radioligand will be accepted for this optional procedure.  
 Parameters eased for this non -
critical test  
[IP_ADDRESS] Proteomic 
and Genetic Biobanking, 
Paragraph 1  Previously read:   Plasma and cellular samples  will be 
collected…  
 
Now reads:  Blood and plasma will be collected…  Improved protocol clarity  
[IP_ADDRESS] Proteomic 
and Genetic Biobanking, Paragraph 2  Previously read:   Cellular samples derived from plasma  
will be retained…  
 
Now reads:  Blood samples will be retained…  
 Improved protocol clarity  
[IP_ADDRESS] Proteomic 
and Genetic Biobanking, 
Paragraph 2  Added: For information regarding future use of stored samples, 
see Section 12.5 Future Use of Stored Specimens . 
 Updated pursuant to direction 
from the agency  
8. Assessment of 
Safety  Added : Assessment of safety will be conducted by [CONTACT_746303] a subject is essential .  Any 
instances of unblinding will be managed as indicated in Section 
10.6.3. 
 Updated study design 
pursuant to direct ion from the 
agency  
8.4.[ADDRESS_1020870]  Previously read:    
• Adverse Events related to increased blood volume  
 
Now reads:  The following will be considered adverse events of 
special interest:  
• AEs related to increased blood volume or shifts of 
fluid between the intravascular and extravascular 
space  
• Suspected transmission of blood- borne infectious 
agents 
 Expanded AESI  
8.5 Stu dy Halting 
Rules, Safety Eval. Meeting  Amended outcomes from Safety Evaluation Meeting to 
align with blinded study design.  Measures added to ensure adequate allocation concealment.  
 Updated study design 
pursuant to direction from the agency  
8.6 Safety 
Oversight  Updated Safety Oversight section and role of Safety 
Evaluation Meetings for blinded study design  Updated study design 
pursuant to direction from the 
 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page 99 of 100   
Location  Description  Purpose  
agency  
10.1 Statistical 
and Analytical 
Plans  Added: The finalization of the SAP will occ ur prior to 
clinical database lock and unblinding of the study data.  Updated study design 
pursuant to direction from the 
agency  
10.[ADDRESS_1020871] changes from baseline for each dosing 
group and among-group differences will (changed from 
“may”) be evaluated . 
 Updated study design 
pursuant to direction from the 
agency  
10.4.[ADDRESS_1020872] been clarified .  Increased 
robustness of general statistical approach regarding primary 
and secondary analysis of endpoints that are continuous as well as categorical .  Update to include subjects randomized 
as part of the disposition summary.  Updated study design 
pursuant to direction from the 
agency  
10.4.3 Analysis 
of Secondary 
Endpoint(s)  Previously read:   Among -group differences may be 
assessed by [CONTACT_179131]-way Analysis of Variance or its 
nonparametric equivalent Kruskal-Wallis  test. 
 
Now reads:  Among-group differences may be assessed by 
[CONTACT_179131]-way Analysis of Covariance (ANCOVA)  or its 
nonparametric equivalent test.  Improved protocol clarity  
10.4.7 Planned 
Interim Analyses  Added: If such an ad hoc safety interim analysis is conducted, 
the treatment assignment will remain masked .   
 Updated study design 
pursuant to direction from the 
agency  
10.[ADDRESS_1020873] target of 40 subjects randomized  (vs. 
enrolled)  Updated study design 
pursuant to direction from the 
agency  
10.6.1 
Enrollment/ Randomization/ Masking Procedures Section  updated to ad dress design deficiencies and  
measures to minimize bias are elucidated .   The trial 
continues to be randomized and is now designed to be blinded to the study subjects, sponsor, investigators, 
medical providers, and outcome assessors.  The details of the enrollment, randomization and masking procedures to 
minimize bias are detailed in this section , including labs . 
 Updated study design 
pursuant to direction from the 
agency  
10.6.2 Evaluation 
of Success of 
Blinding  Section added.  Updated study design 
pursuant to direction from the 
agency  
10.6.3 Breaking 
the Study Blind/ 
Participant Code  Section added.  Updated study design 
pursuant to direction from the 
agency  
12.[ADDRESS_1020874], Updated pursuant to direction 
from the agency  
 
Protocol# ALK6019-201     v7.0_02NOV2018 
 
__________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY   Page [ADDRESS_1020875] 
transfers ownership to another commercial sponsor.  
19.  Revision 
History  Addition of revision history table for Protocol Version 2.0 
dated 09NOV2017  Version control  
 